kw1	kw2	crit_p	edge_weight	inv_edge_weight	iteration	pg	R1C1
abdominal pain/chemically induced	antineoplastic agents immunological/therapeutic use	0.0013888221509739	0.032258064516129	0.830190299122522	0	0.0005888664151666	1
abdominal pain/chemically induced	disease progression	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
abdominal pain/chemically induced	enterocolitis/chemically induced	1.0197981792359201e-09	0.021505376344086	0.830190299122522	0	9.620737539961509e-11	1
abdominal pain/chemically induced	gastritis/complications	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
abdominal pain/chemically induced	glucocorticoids/therapeutic use	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
abdominal pain/chemically induced	neoplasms/drug therapy	0.008650672897396	0.129032258064516	0.830190299122522	0	0.0046517769353922	1
antineoplastic agents immunological/therapeutic use	disease progression	0.0013888221509739	0.032258064516129	0.830190299122522	0	0.0005888664151666	1
antineoplastic agents immunological/therapeutic use	enterocolitis/chemically induced	0.0061761120560381	0.0638148667601683	0.830190299122522	0	0.0031884016641496	1
antineoplastic agents immunological/therapeutic use	gastritis/complications	0.0013888221509739	0.032258064516129	0.830190299122522	0	0.0005888664151666	1
antineoplastic agents immunological/therapeutic use	glucocorticoids/therapeutic use	0.0013888221509739	0.032258064516129	0.830190299122522	0	0.0005888664151666	1
disease progression	enterocolitis/chemically induced	1.0197981792359201e-09	0.021505376344086	0.830190299122522	0	9.620737539961509e-11	1
disease progression	gastritis/complications	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
disease progression	glucocorticoids/therapeutic use	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
disease progression	neoplasms/drug therapy	0.008650672897396	0.129032258064516	0.830190299122522	0	0.0046517769353922	1
enterocolitis/chemically induced	colitis ulcerative/physiopathology	0.0	0.021505376344086	0.830190299122522	0	0.0	1
enterocolitis/chemically induced	crohn disease/physiopathology	0.0	0.021505376344086	0.830190299122522	0	0.0	1
enterocolitis/chemically induced	gastritis/complications	1.0197981792359201e-09	0.021505376344086	0.830190299122522	0	9.620737539961509e-11	1
enterocolitis/chemically induced	glucocorticoids/therapeutic use	1.0197981792359201e-09	0.021505376344086	0.830190299122522	0	9.620737539961509e-11	1
gastritis/complications	glucocorticoids/therapeutic use	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
gastritis/complications	neoplasms/drug therapy	0.008650672897396	0.129032258064516	0.830190299122522	0	0.0046517769353922	1
glucocorticoids/therapeutic use	neoplasms/drug therapy	0.008650672897396	0.129032258064516	0.830190299122522	0	0.0046517769353922	1
neoplasms/drug therapy	AHR	0.0003281348458297	0.129032258064516	0.830190299122522	0	0.0001112700446812	1
neoplasms/drug therapy	anti-bacterial agents/adverse effects	0.0026891839170452	0.129032258064516	0.830190299122522	0	0.0012043173595439	1
neoplasms/drug therapy	biological products/therapeutic use	0.0003281348458297	0.129032258064516	0.830190299122522	0	0.0001112700446812	1
neoplasms/drug therapy	biomarkers/analysis	0.0010715617451913	0.129032258064516	0.830190299122522	0	0.0004436759846442	1
neoplasms/drug therapy	butyrates/metabolism	3.07142551289074e-06	0.129032258064516	0.830190299122522	0	4.86148063361114e-07	1
neoplasms/drug therapy	chemical and drug induced liver injury/diagnosis	3.07142551289074e-06	0.129032258064516	0.830190299122522	0	4.86148063361114e-07	1
neoplasms/drug therapy	clostridium infections/chemically induced	0.0026891839170452	0.129032258064516	0.830190299122522	0	0.0012043173595439	1
neoplasms/drug therapy	colitis/chemically induced	0.0037111950599129	0.126233984373546	5.36975220686589e-05	0	0.0017136073625698	11
neoplasms/drug therapy	colon/immunology	1.25589414996662e-08	0.0154277699859747	0.584635003932401	0	1.6323991047784102e-09	2
neoplasms/drug therapy	diarrhea/chemically induced	0.0002516978247196	0.0161314791677859	0.0777468263617441	0	6.95203111253928e-05	5
neoplasms/drug therapy	escherichia coli infections/drug therapy	0.0026891839170452	0.129032258064516	0.830190299122522	0	0.0012043173595439	1
neoplasms/drug therapy	feces/chemistry	0.0010715617451913	0.129032258064516	0.830190299122522	0	0.0004436759846442	1
neoplasms/drug therapy	hepatitis/diagnosis	3.07142551289074e-06	0.129032258064516	0.830190299122522	0	4.86148063361114e-07	1
neoplasms/drug therapy	immune checkpoint inhibitors/adverse effects	0.0002635619546159	0.0079594183628137	5.36975220686589e-05	0	7.30735188636533e-05	11
neoplasms/drug therapy	intestinal mucosa/immunology	5.4994032065045e-05	0.129032258064516	0.830190299122522	0	1.4296142507475e-05	1
neoplasms/drug therapy	leukocyte l1 antigen complex/analysis	0.0010715617451913	0.129032258064516	0.830190299122522	0	0.0004436759846442	1
neoplasms/drug therapy	protein kinase inhibitors/therapeutic use	0.0026891839170452	0.129032258064516	0.830190299122522	0	0.0012043173595439	1
neoplasms/drug therapy	t-lymphocyte subsets/immunology	5.4994032065045e-05	0.129032258064516	0.830190299122522	0	1.4296142507475e-05	1
neoplasms/drug therapy	tryptophan/pharmacology	0.0003281348458297	0.129032258064516	0.830190299122522	0	0.0001112700446812	1
neoplasms/drug therapy	virus diseases/etiology	0.0026891839170452	0.129032258064516	0.830190299122522	0	0.0012043173595439	1
ACAD8	carcinoma non-small-cell lung/complications	2.14198999312825e-08	0.021505376344086	0.830190299122522	0	2.89640156303506e-09	1
ACAD8	colon/drug effects	0.0063786076318945	0.0638148667601683	0.830190299122522	0	0.0033230272463853	1
ACAD8	CRP	2.14198999312825e-08	0.021505376344086	0.830190299122522	0	2.89640156303506e-09	1
ACAD8	drug-related side effects and adverse reactions	2.07484813671004e-05	0.0427769985974754	0.830190299122522	0	3.63207168585511e-06	1
ACAD8	immune checkpoint inhibitors/pharmacology	0.001771405992799	0.0846189808321645	0.830190299122522	0	0.0007650097159677	1
ACAD8	infliximab/administration & dosage	2.14198999312825e-08	0.021505376344086	0.830190299122522	0	2.89640156303506e-09	1
ACAD8	melanoma/complications	0.0013705798087225	0.0638148667601683	0.830190299122522	0	0.0005782582526319	1
ACAD8	mesalamine/pharmacology	2.14198999312825e-08	0.021505376344086	0.830190299122522	0	2.89640156303506e-09	1
ACAD8	protective agents/pharmacology	2.14198999312825e-08	0.021505376344086	0.830190299122522	0	2.89640156303506e-09	1
ACAD8	trinitrobenzenesulfonic acid/adverse effects	2.14198999312825e-08	0.021505376344086	0.830190299122522	0	2.89640156303506e-09	1
ACAD8	urothelium/drug effects	2.14198999312825e-08	0.021505376344086	0.830190299122522	0	2.89640156303506e-09	1
carcinoma non-small-cell lung/complications	CRP	0.0	0.010752688172043	0.830190299122522	0	0.0	1
carcinoma non-small-cell lung/complications	drug-related side effects and adverse reactions	4.59846172700811e-10	0.021505376344086	0.830190299122522	0	4.16946477344027e-11	1
carcinoma non-small-cell lung/complications	immune checkpoint inhibitors/administration & dosage	0.0020084704002361	0.043010752688172	0.830190299122522	0	0.000872653019809	1
carcinoma non-small-cell lung/complications	infliximab/administration & dosage	0.0	0.010752688172043	0.830190299122522	0	0.0	1
carcinoma non-small-cell lung/complications	melanoma/complications	4.85297920743299e-06	0.032258064516129	0.830190299122522	0	8.11373358056144e-07	1
carcinoma non-small-cell lung/complications	urothelium/drug effects	0.0	0.010752688172043	0.830190299122522	0	0.0	1
colon/drug effects	CD4	0.0080231092761845	0.063143445435827	0.819246405977949	1	0.0044756364491657	1
colon/drug effects	CD68	0.0080231092761845	0.063143445435827	0.819246405977949	1	0.0044756364491657	1
colon/drug effects	cd8-positive t-lymphocytes/drug effects	8.30214330721145e-06	0.0007012622720897	0.584635003932401	0	1.42285160453781e-06	2
colon/drug effects	colitis ulcerative/immunology	8.30214330721145e-06	0.0007012622720897	0.584635003932401	0	1.42285160453781e-06	2
colon/drug effects	crohn disease/immunology	0.0004664777824253	0.032258064516129	0.830190299122522	0	0.0001660054582111	1
colon/drug effects	graft vs host disease/immunology	0.0004664777824253	0.032258064516129	0.830190299122522	0	0.0001660054582111	1
colon/drug effects	immunologic memory/drug effects	0.0023588076889209	0.032258064516129	0.830190299122522	0	0.0010372325214909	1
colon/drug effects	interferon-gamma/metabolism	0.0023588076889209	0.032258064516129	0.830190299122522	0	0.0010372325214909	1
colon/drug effects	macrophages/drug effects	0.0004664777824253	0.032258064516129	0.830190299122522	0	0.0001660054582111	1
colon/drug effects	mesalamine/pharmacology	8.71793207141907e-05	0.032258064516129	0.830190299122522	0	2.34397230222116e-05	1
colon/drug effects	phenotype	8.30214330721145e-06	0.0007012622720897	0.584635003932401	0	1.42285160453781e-06	2
colon/drug effects	protective agents/pharmacology	8.71793207141907e-05	0.032258064516129	0.830190299122522	0	2.34397230222116e-05	1
colon/drug effects	trinitrobenzenesulfonic acid/adverse effects	8.71793207141907e-05	0.032258064516129	0.830190299122522	0	2.34397230222116e-05	1
colon/drug effects	CD8A	0.0088460707221292	0.0064389697648376	0.5583234571556446	2	0.0051214093654432	2
CRP	drug-related side effects and adverse reactions	4.59846172700811e-10	0.021505376344086	0.830190299122522	0	4.16946477344027e-11	1
CRP	immune checkpoint inhibitors/administration & dosage	0.0020084704002361	0.043010752688172	0.830190299122522	0	0.000872653019809	1
CRP	infliximab/administration & dosage	0.0	0.010752688172043	0.830190299122522	0	0.0	1
CRP	melanoma/complications	4.85297920743299e-06	0.032258064516129	0.830190299122522	0	8.11373358056144e-07	1
CRP	urothelium/drug effects	0.0	0.010752688172043	0.830190299122522	0	0.0	1
drug-related side effects and adverse reactions	infliximab/administration & dosage	4.59846172700811e-10	0.021505376344086	0.830190299122522	0	4.16946477344027e-11	1
drug-related side effects and adverse reactions	infliximab/adverse effects	0.0004899257830345	0.0846189808321645	0.830190299122522	0	0.0001746066731989	1
drug-related side effects and adverse reactions	melanoma/complications	0.0003619960532727	0.0638148667601683	0.830190299122522	0	0.000124270133592	1
drug-related side effects and adverse reactions	melanoma/drug therapy	0.0023588076889209	0.105189340813464	0.830190299122522	0	0.0010372325214909	1
drug-related side effects and adverse reactions	TNF	0.0003619960532727	0.0638148667601683	0.830190299122522	0	0.000124270133592	1
drug-related side effects and adverse reactions	urothelium/drug effects	4.59846172700811e-10	0.021505376344086	0.830190299122522	0	4.16946477344027e-11	1
immune checkpoint inhibitors/pharmacology	AHR	7.74320237197327e-09	0.043010752688172	0.830190299122522	0	8.488771907622091e-10	1
immune checkpoint inhibitors/pharmacology	b7-h1 antigen/metabolism	1.53548253129985e-06	0.043010752688172	0.830190299122522	0	2.36599509539914e-07	1
immune checkpoint inhibitors/pharmacology	colitis collagenous/drug therapy	9.068402745145001e-11	0.043010752688172	0.830190299122522	0	6.36879438076221e-12	1
immune checkpoint inhibitors/pharmacology	colitis/diagnosis	0.0001541065520756	0.0846189808321645	0.830190299122522	0	4.23227637775803e-05	1
immune checkpoint inhibitors/pharmacology	gastrointestinal tract/metabolism	1.53548253129985e-06	0.043010752688172	0.830190299122522	0	2.36599509539914e-07	1
immune checkpoint inhibitors/pharmacology	IL22	0.0084684128501298	0.0846189808321645	0.830190299122522	0	0.0045271389450379	1
immune checkpoint inhibitors/pharmacology	inflammatory bowel diseases	0.0002777578837603	0.0846189808321645	0.830190299122522	0	9.10500023044714e-05	1
immune checkpoint inhibitors/pharmacology	melanoma/complications	0.0076274818889516	0.123571364626541	0.819246405977949	1	0.0042474605028671	1
immune checkpoint inhibitors/pharmacology	mesalamine/pharmacology	8.22829201465502e-06	0.043010752688172	0.830190299122522	0	1.3929446125438e-06	1
immune checkpoint inhibitors/pharmacology	programmed cell death 1 receptor/metabolism	1.53548253129985e-06	0.043010752688172	0.830190299122522	0	2.36599509539914e-07	1
immune checkpoint inhibitors/pharmacology	protective agents/pharmacology	8.22829201465502e-06	0.043010752688172	0.830190299122522	0	1.3929446125438e-06	1
immune checkpoint inhibitors/pharmacology	skin neoplasms/complications	9.068402745145001e-11	0.043010752688172	0.830190299122522	0	6.36879438076221e-12	1
immune checkpoint inhibitors/pharmacology	trinitrobenzenesulfonic acid/adverse effects	8.22829201465502e-06	0.043010752688172	0.830190299122522	0	1.3929446125438e-06	1
immune checkpoint inhibitors/pharmacology	tryptophan/pharmacology	7.74320237197327e-09	0.043010752688172	0.830190299122522	0	8.488771907622091e-10	1
infliximab/administration & dosage	immune checkpoint inhibitors/administration & dosage	0.0020084704002361	0.043010752688172	0.830190299122522	0	0.000872653019809	1
infliximab/administration & dosage	melanoma/complications	4.85297920743299e-06	0.032258064516129	0.830190299122522	0	8.11373358056144e-07	1
infliximab/administration & dosage	urothelium/drug effects	0.0	0.010752688172043	0.830190299122522	0	0.0	1
melanoma/complications	antibodies monoclonal/adverse effects	0.0001046640348681	0.032258064516129	0.830190299122522	0	2.84150786487025e-05	1
melanoma/complications	colitis collagenous/drug therapy	3.2361190650275496e-11	0.032258064516129	0.830190299122522	0	2.20490292690556e-12	1
melanoma/complications	lymphocytes/drug effects	0.0001046640348681	0.032258064516129	0.830190299122522	0	2.84150786487025e-05	1
melanoma/complications	neutrophils/drug effects	0.0001046640348681	0.032258064516129	0.830190299122522	0	2.84150786487025e-05	1
melanoma/complications	skin neoplasms/complications	3.2361190650275496e-11	0.032258064516129	0.830190299122522	0	2.20490292690556e-12	1
melanoma/complications	urothelium/drug effects	4.85297920743299e-06	0.032258064516129	0.830190299122522	0	8.11373358056144e-07	1
melanoma/complications	vitamin d/administration & dosage	0.0001046640348681	0.032258064516129	0.830190299122522	0	2.84150786487025e-05	1
mesalamine/pharmacology	protective agents/pharmacology	0.0	0.010752688172043	0.830190299122522	0	0.0	1
mesalamine/pharmacology	trinitrobenzenesulfonic acid/adverse effects	0.0	0.010752688172043	0.830190299122522	0	0.0	1
protective agents/pharmacology	trinitrobenzenesulfonic acid/adverse effects	0.0	0.010752688172043	0.830190299122522	0	0.0	1
urothelium/drug effects	immune checkpoint inhibitors/administration & dosage	0.0020084704002361	0.043010752688172	0.830190299122522	0	0.000872653019809	1
adenocarcinoma of lung/drug therapy	b7-h1 antigen/antagonists & inhibitors	7.74320237197327e-09	0.032258064516129	0.830190299122522	0	8.488771907622091e-10	1
adenocarcinoma of lung/drug therapy	biomarkers/metabolism	0.0	0.010752688172043	0.830190299122522	0	0.0	1
adenocarcinoma of lung/drug therapy	glycoproteins/metabolism	0.0	0.010752688172043	0.830190299122522	0	0.0	1
b7-h1 antigen/antagonists & inhibitors	biomarkers/metabolism	7.74320237197327e-09	0.032258064516129	0.830190299122522	0	8.488771907622091e-10	1
b7-h1 antigen/antagonists & inhibitors	CD274	0.0005814517869145	0.0035063113604488	0.347909608055624	0	0.0002239297954592	3
b7-h1 antigen/antagonists & inhibitors	colitis/epidemiology	7.74320237197327e-09	0.032258064516129	0.830190299122522	0	8.488771907622091e-10	1
b7-h1 antigen/antagonists & inhibitors	glycoproteins/metabolism	7.74320237197327e-09	0.032258064516129	0.830190299122522	0	8.488771907622091e-10	1
b7-h1 antigen/antagonists & inhibitors	neoplasms/complications	0.0016572450205467	0.0946781129109319	0.830190299122522	0	0.0007148389160953	1
b7-h1 antigen/antagonists & inhibitors	programmed cell death 1 receptor/antagonists & inhibitors	0.0047603611986383	0.0187722515913259	0.584635003932401	0	0.0023776856511018	2
biomarkers/metabolism	glycoproteins/metabolism	0.0	0.010752688172043	0.830190299122522	0	0.0	1
adrenal cortex hormones/pharmacology	immune checkpoint inhibitors/adverse effects	0.0091356041252636	0.563829787234043	0.819246405977949	1	0.0052037117615472	1
immune checkpoint inhibitors/adverse effects	anti-bacterial agents	0.0091356041252636	0.563829787234043	0.819246405977949	1	0.0052037117615472	1
immune checkpoint inhibitors/adverse effects	antineoplastic agents immunological/adverse effects	0.0097794752993721	0.016270764526575	0.010308700389748	0	0.0053254060985574	7
immune checkpoint inhibitors/adverse effects	colitis/chemically induced	0.0002413276711882	0.28552761772611	1e-15	0	6.64030541791538e-05	41
immune checkpoint inhibitors/adverse effects	gastritis/chemically induced	0.0091356041252636	0.563829787234043	0.819246405977949	1	0.0052037117615472	1
immune checkpoint inhibitors/adverse effects	mycophenolic acid	0.0091356041252636	0.563829787234043	0.819246405977949	1	0.0052037117615472	1
immune checkpoint inhibitors/adverse effects	nivolumab/adverse effects	0.0036716345069405	0.149573662209081	0.0008903144156418	0	0.0016934163344379	9
adrenal cortex hormones/therapeutic use	antineoplastic agents/adverse effects	0.007113781094266	0.0425531914893617	0.819246405977949	1	0.003954425372989	1
adrenal cortex hormones/therapeutic use	apoptosis/drug effects	0.007113781094266	0.0425531914893617	0.819246405977949	1	0.003954425372989	1
adrenal cortex hormones/therapeutic use	beclomethasone/adverse effects	1.8672532270391797e-11	0.032258064516129	0.830190299122522	0	1.2526646386845599e-12	1
adrenal cortex hormones/therapeutic use	biological products/therapeutic use	1.8672532270391797e-11	0.032258064516129	0.830190299122522	0	1.2526646386845599e-12	1
adrenal cortex hormones/therapeutic use	class i phosphatidylinositol 3-kinases/antagonists & inhibitors	0.007113781094266	0.0425531914893617	0.819246405977949	1	0.003954425372989	1
adrenal cortex hormones/therapeutic use	colon/chemistry	0.007113781094266	0.0425531914893617	0.819246405977949	1	0.003954425372989	1
adrenal cortex hormones/therapeutic use	diarrhea/chemically induced	8.16889101813573e-06	0.002805049088359	0.347909608055624	0	1.37004461520096e-06	3
adrenal cortex hormones/therapeutic use	inflammation/drug therapy	0.0011838553418347	0.0638148667601683	0.830190299122522	0	0.0004982368131516	1
adrenal cortex hormones/therapeutic use	intestinal mucosa/chemistry	0.007113781094266	0.0425531914893617	0.819246405977949	1	0.003954425372989	1
adrenal cortex hormones/therapeutic use	leukemia lymphocytic chronic b-cell/drug therapy	0.007113781094266	0.0425531914893617	0.819246405977949	1	0.003954425372989	1
adrenal cortex hormones/therapeutic use	lymphocytosis/chemically induced	0.007113781094266	0.0425531914893617	0.819246405977949	1	0.003954425372989	1
adrenal cortex hormones/therapeutic use	lymphoma non-hodgkin/drug therapy	0.007113781094266	0.0425531914893617	0.819246405977949	1	0.003954425372989	1
adrenal cortex hormones/therapeutic use	PIK3CD	0.007113781094266	0.0425531914893617	0.819246405977949	1	0.003954425372989	1
adrenal cortex hormones/therapeutic use	protein kinase inhibitors/adverse effects	0.007113781094266	0.0425531914893617	0.819246405977949	1	0.003954425372989	1
adrenal cortex hormones/therapeutic use	purines/adverse effects	0.007113781094266	0.0425531914893617	0.819246405977949	1	0.003954425372989	1
adrenal cortex hormones/therapeutic use	quinazolinones/adverse effects	0.007113781094266	0.0425531914893617	0.819246405977949	1	0.003954425372989	1
adrenal cortex hormones/therapeutic use	skin neoplasms/drug therapy	0.0005814517869145	0.0638148667601683	0.830190299122522	0	0.0002334339983105	1
adrenal cortex hormones/therapeutic use	SNCA	0.0021230700654632	0.0946781129109319	0.830190299122522	0	0.0009302340538402	1
adrenal cortex hormones/therapeutic use	TNF	0.0026891839170452	0.0946781129109319	0.830190299122522	0	0.0012219719371479	1
adrenal cortex hormones/therapeutic use	tumor necrosis factor inhibitors	1.50681043810751e-07	0.032258064516129	0.830190299122522	0	2.25073886195304e-08	1
antineoplastic agents/adverse effects	apoptosis/drug effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
antineoplastic agents/adverse effects	biomarkers/analysis	0.0006571705393096	0.0212765957446808	0.819246405977949	1	0.0002818746185764	1
antineoplastic agents/adverse effects	class i phosphatidylinositol 3-kinases/antagonists & inhibitors	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
antineoplastic agents/adverse effects	colon/chemistry	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
antineoplastic agents/adverse effects	intestinal mucosa/chemistry	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
antineoplastic agents/adverse effects	leukemia lymphocytic chronic b-cell/drug therapy	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
antineoplastic agents/adverse effects	lymphocytosis/chemically induced	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
antineoplastic agents/adverse effects	lymphoma non-hodgkin/drug therapy	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
antineoplastic agents/adverse effects	PIK3CD	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
antineoplastic agents/adverse effects	protein kinase inhibitors/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
antineoplastic agents/adverse effects	purines/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
antineoplastic agents/adverse effects	quinazolinones/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
antineoplastic agents/adverse effects	recurrence	0.0004762611710998	0.0212765957446808	0.819246405977949	1	0.0001984421546249	1
apoptosis/drug effects	biomarkers/analysis	0.0006571705393096	0.0212765957446808	0.819246405977949	1	0.0002818746185764	1
apoptosis/drug effects	class i phosphatidylinositol 3-kinases/antagonists & inhibitors	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
apoptosis/drug effects	colon/chemistry	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
apoptosis/drug effects	intestinal mucosa/chemistry	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
apoptosis/drug effects	leukemia lymphocytic chronic b-cell/drug therapy	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
apoptosis/drug effects	lymphocytosis/chemically induced	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
apoptosis/drug effects	lymphoma non-hodgkin/drug therapy	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
apoptosis/drug effects	PIK3CD	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
apoptosis/drug effects	protein kinase inhibitors/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
apoptosis/drug effects	purines/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
apoptosis/drug effects	quinazolinones/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
apoptosis/drug effects	recurrence	0.0004762611710998	0.0212765957446808	0.819246405977949	1	0.0001984421546249	1
beclomethasone/adverse effects	diarrhea/chemically induced	0.0027158912620093	0.150537634408602	0.830190299122522	0	0.001239801514261	1
beclomethasone/adverse effects	immune checkpoint inhibitors	0.0088335817030947	0.319148936170213	0.819246405977949	1	0.004953734053108	1
beclomethasone/adverse effects	inflammation/drug therapy	1.90948322242736e-10	0.021505376344086	0.830190299122522	0	1.69131375571396e-11	1
biological products/therapeutic use	diarrhea/chemically induced	0.0027158912620093	0.150537634408602	0.830190299122522	0	0.001239801514261	1
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	biomarkers/analysis	0.0006571705393096	0.0212765957446808	0.819246405977949	1	0.0002818746185764	1
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	colon/chemistry	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	intestinal mucosa/chemistry	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	leukemia lymphocytic chronic b-cell/drug therapy	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	lymphocytosis/chemically induced	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	lymphoma non-hodgkin/drug therapy	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	PIK3CD	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	protein kinase inhibitors/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	purines/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	quinazolinones/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
class i phosphatidylinositol 3-kinases/antagonists & inhibitors	recurrence	0.0004762611710998	0.0212765957446808	0.819246405977949	1	0.0001984421546249	1
colon/chemistry	biomarkers/analysis	0.0006571705393096	0.0212765957446808	0.819246405977949	1	0.0002818746185764	1
colon/chemistry	intestinal mucosa/chemistry	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
colon/chemistry	leukemia lymphocytic chronic b-cell/drug therapy	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
colon/chemistry	lymphocytosis/chemically induced	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
colon/chemistry	lymphoma non-hodgkin/drug therapy	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
colon/chemistry	PIK3CD	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
colon/chemistry	protein kinase inhibitors/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
colon/chemistry	purines/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
colon/chemistry	quinazolinones/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
colon/chemistry	recurrence	0.0004762611710998	0.0212765957446808	0.819246405977949	1	0.0001984421546249	1
diarrhea/chemically induced	biomarkers/analysis	0.0064907348469864	0.150537634408602	0.830190299122522	0	0.0033916470872356	1
diarrhea/chemically induced	feces	0.0027158912620093	0.150537634408602	0.830190299122522	0	0.001239801514261	1
diarrhea/chemically induced	feces/chemistry	0.0064907348469864	0.150537634408602	0.830190299122522	0	0.0033916470872356	1
diarrhea/chemically induced	leukocyte l1 antigen complex/analysis	0.0064907348469864	0.150537634408602	0.830190299122522	0	0.0033916470872356	1
diarrhea/chemically induced	LTF	0.0027158912620093	0.150537634408602	0.830190299122522	0	0.001239801514261	1
inflammation/drug therapy	cd8-positive t-lymphocytes/cytology	0.00036582514696	0.021505376344086	0.830190299122522	0	0.0001276936833728	1
inflammation/drug therapy	chemokines/metabolism	0.00036582514696	0.021505376344086	0.830190299122522	0	0.0001276936833728	1
inflammation/drug therapy	colitis/drug therapy	0.005535058163635	0.0638148667601683	0.830190299122522	0	0.0028052417422615	1
inflammation/drug therapy	ctla-4 antigen/immunology	0.00036582514696	0.021505376344086	0.830190299122522	0	0.0001276936833728	1
inflammation/drug therapy	gene expression regulation/genetics	0.00036582514696	0.021505376344086	0.830190299122522	0	0.0001276936833728	1
inflammation/drug therapy	melanoma/genetics	0.00036582514696	0.021505376344086	0.830190299122522	0	0.0001276936833728	1
inflammation/drug therapy	multigene family	0.00036582514696	0.021505376344086	0.830190299122522	0	0.0001276936833728	1
inflammation/drug therapy	myeloid cells/cytology	0.00036582514696	0.021505376344086	0.830190299122522	0	0.0001276936833728	1
inflammation/drug therapy	receptors antigen t-cell/genetics	0.00036582514696	0.021505376344086	0.830190299122522	0	0.0001276936833728	1
inflammation/drug therapy	receptors cxcr3/genetics	0.00036582514696	0.021505376344086	0.830190299122522	0	0.0001276936833728	1
inflammation/drug therapy	receptors cxcr6/genetics	0.00036582514696	0.021505376344086	0.830190299122522	0	0.0001276936833728	1
inflammation/drug therapy	t-lymphocytes regulatory/cytology	0.00036582514696	0.021505376344086	0.830190299122522	0	0.0001276936833728	1
intestinal mucosa/chemistry	biomarkers/analysis	0.0006571705393096	0.0212765957446808	0.819246405977949	1	0.0002818746185764	1
intestinal mucosa/chemistry	leukemia lymphocytic chronic b-cell/drug therapy	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
intestinal mucosa/chemistry	lymphocytosis/chemically induced	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
intestinal mucosa/chemistry	lymphoma non-hodgkin/drug therapy	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
intestinal mucosa/chemistry	PIK3CD	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
intestinal mucosa/chemistry	protein kinase inhibitors/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
intestinal mucosa/chemistry	purines/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
intestinal mucosa/chemistry	quinazolinones/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
intestinal mucosa/chemistry	recurrence	0.0004762611710998	0.0212765957446808	0.819246405977949	1	0.0001984421546249	1
leukemia lymphocytic chronic b-cell/drug therapy	biomarkers/analysis	0.0006571705393096	0.0212765957446808	0.819246405977949	1	0.0002818746185764	1
leukemia lymphocytic chronic b-cell/drug therapy	lymphocytosis/chemically induced	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
leukemia lymphocytic chronic b-cell/drug therapy	lymphoma non-hodgkin/drug therapy	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
leukemia lymphocytic chronic b-cell/drug therapy	PIK3CD	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
leukemia lymphocytic chronic b-cell/drug therapy	protein kinase inhibitors/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
leukemia lymphocytic chronic b-cell/drug therapy	purines/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
leukemia lymphocytic chronic b-cell/drug therapy	quinazolinones/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
leukemia lymphocytic chronic b-cell/drug therapy	recurrence	0.0004762611710998	0.0212765957446808	0.819246405977949	1	0.0001984421546249	1
lymphocytosis/chemically induced	biomarkers/analysis	0.0006571705393096	0.0212765957446808	0.819246405977949	1	0.0002818746185764	1
lymphocytosis/chemically induced	lymphoma non-hodgkin/drug therapy	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
lymphocytosis/chemically induced	PIK3CD	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
lymphocytosis/chemically induced	protein kinase inhibitors/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
lymphocytosis/chemically induced	purines/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
lymphocytosis/chemically induced	quinazolinones/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
lymphocytosis/chemically induced	recurrence	0.0004762611710998	0.0212765957446808	0.819246405977949	1	0.0001984421546249	1
lymphoma non-hodgkin/drug therapy	biomarkers/analysis	0.0006571705393096	0.0212765957446808	0.819246405977949	1	0.0002818746185764	1
lymphoma non-hodgkin/drug therapy	PIK3CD	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
lymphoma non-hodgkin/drug therapy	protein kinase inhibitors/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
lymphoma non-hodgkin/drug therapy	purines/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
lymphoma non-hodgkin/drug therapy	quinazolinones/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
lymphoma non-hodgkin/drug therapy	recurrence	0.0004762611710998	0.0212765957446808	0.819246405977949	1	0.0001984421546249	1
PIK3CD	biomarkers/analysis	0.0006571705393096	0.0212765957446808	0.819246405977949	1	0.0002818746185764	1
PIK3CD	protein kinase inhibitors/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
PIK3CD	purines/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
PIK3CD	quinazolinones/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
PIK3CD	recurrence	0.0004762611710998	0.0212765957446808	0.819246405977949	1	0.0001984421546249	1
protein kinase inhibitors/adverse effects	biomarkers/analysis	0.0006571705393096	0.0212765957446808	0.819246405977949	1	0.0002818746185764	1
protein kinase inhibitors/adverse effects	purines/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
protein kinase inhibitors/adverse effects	quinazolinones/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
protein kinase inhibitors/adverse effects	recurrence	0.0004762611710998	0.0212765957446808	0.819246405977949	1	0.0001984421546249	1
purines/adverse effects	biomarkers/analysis	0.0006571705393096	0.0212765957446808	0.819246405977949	1	0.0002818746185764	1
purines/adverse effects	quinazolinones/adverse effects	6.39835881371809e-05	0.0106382978723404	0.819246405977949	1	1.81600478095234e-05	1
purines/adverse effects	recurrence	0.0004762611710998	0.0212765957446808	0.819246405977949	1	0.0001984421546249	1
quinazolinones/adverse effects	biomarkers/analysis	0.0006571705393096	0.0212765957446808	0.819246405977949	1	0.0002818746185764	1
quinazolinones/adverse effects	recurrence	0.0004762611710998	0.0212765957446808	0.819246405977949	1	0.0001984421546249	1
skin neoplasms/drug therapy	colon/diagnostic imaging	3.69687694073866e-06	0.021505376344086	0.830190299122522	0	6.08395890666635e-07	1
skin neoplasms/drug therapy	drug resistance/immunology	3.69687694073866e-06	0.021505376344086	0.830190299122522	0	6.08395890666635e-07	1
skin neoplasms/drug therapy	glucocorticoids/pharmacology	3.69687694073866e-06	0.021505376344086	0.830190299122522	0	6.08395890666635e-07	1
skin neoplasms/drug therapy	immunosuppressive agents/pharmacology	3.69687694073866e-06	0.021505376344086	0.830190299122522	0	6.08395890666635e-07	1
skin neoplasms/drug therapy	infliximab/adverse effects	0.0034087164993381	0.0846189808321645	0.830190299122522	0	0.0015703678212359	1
skin neoplasms/drug therapy	intestinal mucosa/diagnostic imaging	3.69687694073866e-06	0.021505376344086	0.830190299122522	0	6.08395890666635e-07	1
skin neoplasms/drug therapy	melanoma/drug therapy	2.36476469860459e-07	0.0023375409069658	0.584635003932401	0	3.54466825891464e-08	2
skin neoplasms/drug therapy	mucositis/chemically induced	3.69687694073866e-06	0.021505376344086	0.830190299122522	0	6.08395890666635e-07	1
skin neoplasms/drug therapy	SNCA	0.0021230700654632	0.0638148667601683	0.830190299122522	0	0.0009302340538402	1
skin neoplasms/drug therapy	TNF	0.0026891839170452	0.0638148667601683	0.830190299122522	0	0.0012219719371479	1
skin neoplasms/drug therapy	tumor necrosis factor inhibitors	1.50681043810751e-07	0.021505376344086	0.830190299122522	0	2.25073886195304e-08	1
SNCA	colitis ulcerative/chemically induced	1.16731049539838e-05	0.032258064516129	0.830190299122522	0	2.03116920582946e-06	1
SNCA	hashimoto disease/chemically induced	1.16731049539838e-05	0.032258064516129	0.830190299122522	0	2.03116920582946e-06	1
SNCA	paclitaxel/therapeutic use	1.16731049539838e-05	0.032258064516129	0.830190299122522	0	2.03116920582946e-06	1
SNCA	squamous cell carcinoma of head and neck/drug therapy	1.16731049539838e-05	0.032258064516129	0.830190299122522	0	2.03116920582946e-06	1
SNCA	TNF	0.0068877258622775	0.0946781129109319	0.830190299122522	0	0.0036748977609006	1
SNCA	tongue neoplasms/drug therapy	1.16731049539838e-05	0.032258064516129	0.830190299122522	0	2.03116920582946e-06	1
SNCA	tumor necrosis factor inhibitors	2.87394303438993e-06	0.032258064516129	0.830190299122522	0	4.50371576143915e-07	1
TNF	CXCL10	4.30118631762015e-05	0.032258064516129	0.830190299122522	0	1.09558519411079e-05	1
TNF	CXCL9	4.30118631762015e-05	0.032258064516129	0.830190299122522	0	1.09558519411079e-05	1
TNF	dermatitis	4.30118631762015e-05	0.032258064516129	0.830190299122522	0	1.09558519411079e-05	1
TNF	immune checkpoint inhibitors	0.0015167734542599	0.0312870859855432	0.347909608055624	0	0.0006526577599305	3
TNF	infliximab/adverse effects	0.0076274818889516	0.123571364626541	0.819246405977949	1	0.0042474605028671	1
TNF	melanoma/drug therapy	8.30214330721145e-06	0.0068584991446141	0.584635003932401	0	1.42285160453781e-06	2
TNF	psoriasis	4.30118631762015e-05	0.032258064516129	0.830190299122522	0	1.09558519411079e-05	1
TNF	rna	4.30118631762015e-05	0.032258064516129	0.830190299122522	0	1.09558519411079e-05	1
TNF	TCIM	4.30118631762015e-05	0.032258064516129	0.830190299122522	0	1.09558519411079e-05	1
TNF	tumor necrosis factor inhibitors	4.85297920743299e-06	0.032258064516129	0.830190299122522	0	8.11373358056144e-07	1
tumor necrosis factor inhibitors	melanoma/drug therapy	8.71793207141907e-05	0.053763440860215	0.830190299122522	0	2.34397230222116e-05	1
adrenal insufficiency/chemically induced	angiogenesis inhibitors/therapeutic use	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
adrenal insufficiency/chemically induced	axitinib/administration & dosage	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
adrenal insufficiency/chemically induced	bevacizumab/administration & dosage	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
adrenal insufficiency/chemically induced	carcinoma renal cell/drug therapy	0.0026891839170452	0.021505376344086	0.830190299122522	0	0.0012219719371479	1
adrenal insufficiency/chemically induced	diabetes mellitus type 1/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
adrenal insufficiency/chemically induced	exanthema/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
adrenal insufficiency/chemically induced	fatigue/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
adrenal insufficiency/chemically induced	hepatitis autoimmune/etiology	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
adrenal insufficiency/chemically induced	hypophysitis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
adrenal insufficiency/chemically induced	ipilimumab/therapeutic use	0.0067591691408641	0.032258064516129	0.830190299122522	0	0.0036027646835737	1
adrenal insufficiency/chemically induced	myasthenia gravis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
adrenal insufficiency/chemically induced	myocarditis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
adrenal insufficiency/chemically induced	nephritis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
adrenal insufficiency/chemically induced	nivolumab/therapeutic use	0.0058034197088005	0.021505376344086	0.830190299122522	0	0.00299295859196	1
adrenal insufficiency/chemically induced	pneumonia/chemically induced	0.0091356041252636	0.0319148936170212	0.819246405977949	1	0.0052037117615472	1
adrenal insufficiency/chemically induced	pruritus/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
adrenal insufficiency/chemically induced	immune checkpoint inhibitors/therapeutic use	0.0091797772502113	0.0208333333333333	0.8148056077504143	2	0.0053848836884015	1
angiogenesis inhibitors/therapeutic use	axitinib/administration & dosage	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
angiogenesis inhibitors/therapeutic use	bevacizumab/administration & dosage	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
angiogenesis inhibitors/therapeutic use	carcinoma renal cell/drug therapy	0.0026891839170452	0.021505376344086	0.830190299122522	0	0.0012219719371479	1
angiogenesis inhibitors/therapeutic use	diabetes mellitus type 1/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
angiogenesis inhibitors/therapeutic use	exanthema/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
angiogenesis inhibitors/therapeutic use	fatigue/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
angiogenesis inhibitors/therapeutic use	hepatitis autoimmune/etiology	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
angiogenesis inhibitors/therapeutic use	hypophysitis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
angiogenesis inhibitors/therapeutic use	ipilimumab/therapeutic use	0.0067591691408641	0.032258064516129	0.830190299122522	0	0.0036027646835737	1
angiogenesis inhibitors/therapeutic use	myasthenia gravis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
angiogenesis inhibitors/therapeutic use	myocarditis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
angiogenesis inhibitors/therapeutic use	nephritis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
angiogenesis inhibitors/therapeutic use	nivolumab/therapeutic use	0.0058034197088005	0.021505376344086	0.830190299122522	0	0.00299295859196	1
angiogenesis inhibitors/therapeutic use	pneumonia/chemically induced	0.0091356041252636	0.0319148936170212	0.819246405977949	1	0.0052037117615472	1
angiogenesis inhibitors/therapeutic use	pruritus/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
angiogenesis inhibitors/therapeutic use	immune checkpoint inhibitors/therapeutic use	0.0091797772502113	0.0208333333333333	0.8148056077504143	2	0.0053848836884015	1
axitinib/administration & dosage	bevacizumab/administration & dosage	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
axitinib/administration & dosage	carcinoma renal cell/drug therapy	0.0026891839170452	0.021505376344086	0.830190299122522	0	0.0012219719371479	1
axitinib/administration & dosage	diabetes mellitus type 1/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
axitinib/administration & dosage	exanthema/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
axitinib/administration & dosage	fatigue/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
axitinib/administration & dosage	hepatitis autoimmune/etiology	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
axitinib/administration & dosage	hypophysitis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
axitinib/administration & dosage	ipilimumab/therapeutic use	0.0067591691408641	0.032258064516129	0.830190299122522	0	0.0036027646835737	1
axitinib/administration & dosage	myasthenia gravis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
axitinib/administration & dosage	myocarditis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
axitinib/administration & dosage	nephritis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
axitinib/administration & dosage	nivolumab/therapeutic use	0.0058034197088005	0.021505376344086	0.830190299122522	0	0.00299295859196	1
axitinib/administration & dosage	pneumonia/chemically induced	0.0091356041252636	0.0319148936170212	0.819246405977949	1	0.0052037117615472	1
axitinib/administration & dosage	pruritus/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
axitinib/administration & dosage	immune checkpoint inhibitors/therapeutic use	0.0091797772502113	0.0208333333333333	0.8148056077504143	2	0.0053848836884015	1
bevacizumab/administration & dosage	carcinoma renal cell/drug therapy	0.0026891839170452	0.021505376344086	0.830190299122522	0	0.0012219719371479	1
bevacizumab/administration & dosage	diabetes mellitus type 1/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
bevacizumab/administration & dosage	exanthema/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
bevacizumab/administration & dosage	fatigue/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
bevacizumab/administration & dosage	hepatitis autoimmune/etiology	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
bevacizumab/administration & dosage	hypophysitis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
bevacizumab/administration & dosage	ipilimumab/therapeutic use	0.0067591691408641	0.032258064516129	0.830190299122522	0	0.0036027646835737	1
bevacizumab/administration & dosage	myasthenia gravis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
bevacizumab/administration & dosage	myocarditis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
bevacizumab/administration & dosage	nephritis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
bevacizumab/administration & dosage	nivolumab/therapeutic use	0.0058034197088005	0.021505376344086	0.830190299122522	0	0.00299295859196	1
bevacizumab/administration & dosage	pneumonia/chemically induced	0.0091356041252636	0.0319148936170212	0.819246405977949	1	0.0052037117615472	1
bevacizumab/administration & dosage	pruritus/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
bevacizumab/administration & dosage	immune checkpoint inhibitors/therapeutic use	0.0091797772502113	0.0208333333333333	0.8148056077504143	2	0.0053848836884015	1
carcinoma renal cell/drug therapy	diabetes mellitus type 1/chemically induced	0.0026891839170452	0.021505376344086	0.830190299122522	0	0.0012219719371479	1
carcinoma renal cell/drug therapy	exanthema/chemically induced	0.0026891839170452	0.021505376344086	0.830190299122522	0	0.0012219719371479	1
carcinoma renal cell/drug therapy	fatigue/chemically induced	0.0026891839170452	0.021505376344086	0.830190299122522	0	0.0012219719371479	1
carcinoma renal cell/drug therapy	hepatitis autoimmune/etiology	0.0026891839170452	0.021505376344086	0.830190299122522	0	0.0012219719371479	1
carcinoma renal cell/drug therapy	hypophysitis/chemically induced	0.0026891839170452	0.021505376344086	0.830190299122522	0	0.0012219719371479	1
carcinoma renal cell/drug therapy	inflammatory bowel diseases/drug therapy	0.0026891839170452	0.0638148667601683	0.830190299122522	0	0.0012219719371479	1
carcinoma renal cell/drug therapy	ipilimumab/therapeutic use	2.19327460827433e-06	0.0007012622720897	0.584635003932401	0	3.41405953174778e-07	2
carcinoma renal cell/drug therapy	myasthenia gravis/chemically induced	0.0026891839170452	0.021505376344086	0.830190299122522	0	0.0012219719371479	1
carcinoma renal cell/drug therapy	myocarditis/chemically induced	0.0026891839170452	0.021505376344086	0.830190299122522	0	0.0012219719371479	1
carcinoma renal cell/drug therapy	nephritis/chemically induced	0.0026891839170452	0.021505376344086	0.830190299122522	0	0.0012219719371479	1
carcinoma renal cell/drug therapy	proton pump inhibitors/adverse effects	3.7119500591544304e-09	0.021505376344086	0.830190299122522	0	3.61856766772917e-10	1
carcinoma renal cell/drug therapy	pruritus/chemically induced	0.0026891839170452	0.021505376344086	0.830190299122522	0	0.0012219719371479	1
diabetes mellitus type 1/chemically induced	exanthema/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
diabetes mellitus type 1/chemically induced	fatigue/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
diabetes mellitus type 1/chemically induced	hepatitis autoimmune/etiology	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
diabetes mellitus type 1/chemically induced	hypophysitis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
diabetes mellitus type 1/chemically induced	ipilimumab/therapeutic use	0.0067591691408641	0.032258064516129	0.830190299122522	0	0.0036027646835737	1
diabetes mellitus type 1/chemically induced	myasthenia gravis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
diabetes mellitus type 1/chemically induced	myocarditis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
diabetes mellitus type 1/chemically induced	nephritis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
diabetes mellitus type 1/chemically induced	nivolumab/therapeutic use	0.0058034197088005	0.021505376344086	0.830190299122522	0	0.00299295859196	1
diabetes mellitus type 1/chemically induced	pneumonia/chemically induced	0.0091356041252636	0.0319148936170212	0.819246405977949	1	0.0052037117615472	1
diabetes mellitus type 1/chemically induced	pruritus/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
diabetes mellitus type 1/chemically induced	immune checkpoint inhibitors/therapeutic use	0.0091797772502113	0.0208333333333333	0.8148056077504143	2	0.0053848836884015	1
exanthema/chemically induced	fatigue/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
exanthema/chemically induced	hepatitis autoimmune/etiology	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
exanthema/chemically induced	hypophysitis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
exanthema/chemically induced	ipilimumab/therapeutic use	0.0067591691408641	0.032258064516129	0.830190299122522	0	0.0036027646835737	1
exanthema/chemically induced	myasthenia gravis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
exanthema/chemically induced	myocarditis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
exanthema/chemically induced	nephritis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
exanthema/chemically induced	nivolumab/therapeutic use	0.0058034197088005	0.021505376344086	0.830190299122522	0	0.00299295859196	1
exanthema/chemically induced	pneumonia/chemically induced	0.0091356041252636	0.0319148936170212	0.819246405977949	1	0.0052037117615472	1
exanthema/chemically induced	pruritus/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
exanthema/chemically induced	immune checkpoint inhibitors/therapeutic use	0.0091797772502113	0.0208333333333333	0.8148056077504143	2	0.0053848836884015	1
fatigue/chemically induced	hepatitis autoimmune/etiology	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
fatigue/chemically induced	hypophysitis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
fatigue/chemically induced	ipilimumab/therapeutic use	0.0067591691408641	0.032258064516129	0.830190299122522	0	0.0036027646835737	1
fatigue/chemically induced	myasthenia gravis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
fatigue/chemically induced	myocarditis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
fatigue/chemically induced	nephritis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
fatigue/chemically induced	nivolumab/therapeutic use	0.0058034197088005	0.021505376344086	0.830190299122522	0	0.00299295859196	1
fatigue/chemically induced	pneumonia/chemically induced	0.0091356041252636	0.0319148936170212	0.819246405977949	1	0.0052037117615472	1
fatigue/chemically induced	pruritus/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
fatigue/chemically induced	immune checkpoint inhibitors/therapeutic use	0.0091797772502113	0.0208333333333333	0.8148056077504143	2	0.0053848836884015	1
hepatitis autoimmune/etiology	hypophysitis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
hepatitis autoimmune/etiology	ipilimumab/therapeutic use	0.0067591691408641	0.032258064516129	0.830190299122522	0	0.0036027646835737	1
hepatitis autoimmune/etiology	myasthenia gravis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
hepatitis autoimmune/etiology	myocarditis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
hepatitis autoimmune/etiology	nephritis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
hepatitis autoimmune/etiology	nivolumab/therapeutic use	0.0058034197088005	0.021505376344086	0.830190299122522	0	0.00299295859196	1
hepatitis autoimmune/etiology	pneumonia/chemically induced	0.0091356041252636	0.0319148936170212	0.819246405977949	1	0.0052037117615472	1
hepatitis autoimmune/etiology	pruritus/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
hepatitis autoimmune/etiology	immune checkpoint inhibitors/therapeutic use	0.0091797772502113	0.0208333333333333	0.8148056077504143	2	0.0053848836884015	1
hypophysitis/chemically induced	ipilimumab/therapeutic use	0.0067591691408641	0.032258064516129	0.830190299122522	0	0.0036027646835737	1
hypophysitis/chemically induced	myasthenia gravis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
hypophysitis/chemically induced	myocarditis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
hypophysitis/chemically induced	nephritis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
hypophysitis/chemically induced	nivolumab/therapeutic use	0.0058034197088005	0.021505376344086	0.830190299122522	0	0.00299295859196	1
hypophysitis/chemically induced	pneumonia/chemically induced	0.0091356041252636	0.0319148936170212	0.819246405977949	1	0.0052037117615472	1
hypophysitis/chemically induced	pruritus/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
hypophysitis/chemically induced	immune checkpoint inhibitors/therapeutic use	0.0091797772502113	0.0208333333333333	0.8148056077504143	2	0.0053848836884015	1
ipilimumab/therapeutic use	carcinoma non-small-cell lung/drug therapy	0.0002585218551055	0.0638148667601683	0.830190299122522	0	7.1540639148715e-05	1
ipilimumab/therapeutic use	inflammatory bowel diseases/drug therapy	0.0067591691408641	0.0946781129109319	0.830190299122522	0	0.0036027646835737	1
ipilimumab/therapeutic use	myasthenia gravis/chemically induced	0.0067591691408641	0.032258064516129	0.830190299122522	0	0.0036027646835737	1
ipilimumab/therapeutic use	myocarditis/chemically induced	0.0067591691408641	0.032258064516129	0.830190299122522	0	0.0036027646835737	1
ipilimumab/therapeutic use	nephritis/chemically induced	0.0067591691408641	0.032258064516129	0.830190299122522	0	0.0036027646835737	1
ipilimumab/therapeutic use	pneumonia/chemically induced	8.23874183480754e-05	0.0020883744586409	0.584635003932401	0	2.19354342352318e-05	2
ipilimumab/therapeutic use	proton pump inhibitors/adverse effects	9.94826330498929e-08	0.032258064516129	0.830190299122522	0	1.4077731091966e-08	1
ipilimumab/therapeutic use	pruritus/chemically induced	0.0067591691408641	0.032258064516129	0.830190299122522	0	0.0036027646835737	1
myasthenia gravis/chemically induced	myocarditis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
myasthenia gravis/chemically induced	nephritis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
myasthenia gravis/chemically induced	nivolumab/therapeutic use	0.0058034197088005	0.021505376344086	0.830190299122522	0	0.00299295859196	1
myasthenia gravis/chemically induced	pneumonia/chemically induced	0.0091356041252636	0.0319148936170212	0.819246405977949	1	0.0052037117615472	1
myasthenia gravis/chemically induced	pruritus/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
myasthenia gravis/chemically induced	immune checkpoint inhibitors/therapeutic use	0.0091797772502113	0.0208333333333333	0.8148056077504143	2	0.0053848836884015	1
myocarditis/chemically induced	nephritis/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
myocarditis/chemically induced	nivolumab/therapeutic use	0.0058034197088005	0.021505376344086	0.830190299122522	0	0.00299295859196	1
myocarditis/chemically induced	pneumonia/chemically induced	0.0091356041252636	0.0319148936170212	0.819246405977949	1	0.0052037117615472	1
myocarditis/chemically induced	pruritus/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
myocarditis/chemically induced	immune checkpoint inhibitors/therapeutic use	0.0091797772502113	0.0208333333333333	0.8148056077504143	2	0.0053848836884015	1
nephritis/chemically induced	nivolumab/therapeutic use	0.0058034197088005	0.021505376344086	0.830190299122522	0	0.00299295859196	1
nephritis/chemically induced	pneumonia/chemically induced	0.0091356041252636	0.0319148936170212	0.819246405977949	1	0.0052037117615472	1
nephritis/chemically induced	pruritus/chemically induced	0.0005814517869145	0.010752688172043	0.830190299122522	0	0.0002334339983105	1
nephritis/chemically induced	immune checkpoint inhibitors/therapeutic use	0.0091797772502113	0.0208333333333333	0.8148056077504143	2	0.0053848836884015	1
nivolumab/therapeutic use	arthritis/chemically induced	7.23479474125828e-05	0.021505376344086	0.830190299122522	0	1.91866149846787e-05	1
nivolumab/therapeutic use	CHI3L1	7.23479474125828e-05	0.021505376344086	0.830190299122522	0	1.91866149846787e-05	1
nivolumab/therapeutic use	CXCL8	7.23479474125828e-05	0.021505376344086	0.830190299122522	0	1.91866149846787e-05	1
nivolumab/therapeutic use	glucocorticoids	7.23479474125828e-05	0.021505376344086	0.830190299122522	0	1.91866149846787e-05	1
nivolumab/therapeutic use	pruritus/chemically induced	0.0058034197088005	0.021505376344086	0.830190299122522	0	0.00299295859196	1
pneumonia/chemically induced	antibodies monoclonal humanized/administration & dosage	0.0002777578837603	0.032258064516129	0.830190299122522	0	9.10500023044714e-05	1
pneumonia/chemically induced	carcinoma non-small-cell lung/drug therapy	0.0005814517869145	0.0638148667601683	0.830190299122522	0	0.0002123977946096	1
pneumonia/chemically induced	dose-response relationship drug	0.0040050466235307	0.0638148667601683	0.830190299122522	0	0.0019308727447	1
pneumonia/chemically induced	drugs investigational/administration & dosage	0.0002777578837603	0.032258064516129	0.830190299122522	0	9.10500023044714e-05	1
pneumonia/chemically induced	neoplasms/diagnosis	0.0002777578837603	0.032258064516129	0.830190299122522	0	9.10500023044714e-05	1
pneumonia/chemically induced	pruritus/chemically induced	0.0091356041252636	0.0319148936170212	0.819246405977949	1	0.0052037117615472	1
pruritus/chemically induced	immune checkpoint inhibitors/therapeutic use	0.0091797772502113	0.0208333333333333	0.8148056077504143	2	0.0053848836884015	1
AHR	IL22	1.4978957415083202e-09	0.021505376344086	0.830190299122522	0	1.4288104033255401e-10	1
AHR	tryptophan/pharmacology	0.0	0.010752688172043	0.830190299122522	0	0.0	1
IL22	BTLA	0.0014984543892913	0.021505376344086	0.830190299122522	0	0.0006439898318757	1
IL22	CD28	0.0014984543892913	0.021505376344086	0.830190299122522	0	0.0006439898318757	1
IL22	CSF2	0.0014984543892913	0.021505376344086	0.830190299122522	0	0.0006439898318757	1
IL22	gastrointestinal neoplasms/drug therapy	0.0014984543892913	0.021505376344086	0.830190299122522	0	0.0006439898318757	1
IL22	HAVCR2	0.0014984543892913	0.021505376344086	0.830190299122522	0	0.0006439898318757	1
IL22	IL15	0.0014984543892913	0.021505376344086	0.830190299122522	0	0.0006439898318757	1
IL22	IL17C	0.0014984543892913	0.021505376344086	0.830190299122522	0	0.0006439898318757	1
IL22	IL21	0.0014984543892913	0.021505376344086	0.830190299122522	0	0.0006439898318757	1
IL22	IL4	0.0014984543892913	0.021505376344086	0.830190299122522	0	0.0006439898318757	1
IL22	IL6	0.0089728790551117	0.0423244108899565	0.819246405977949	1	0.0050362482931877	1
IL22	immune system diseases/drug therapy	0.0014984543892913	0.021505376344086	0.830190299122522	0	0.0006439898318757	1
IL22	LIF	0.0014984543892913	0.021505376344086	0.830190299122522	0	0.0006439898318757	1
IL22	tryptophan/pharmacology	1.4978957415083202e-09	0.021505376344086	0.830190299122522	0	1.4288104033255401e-10	1
anti-bacterial agents/adverse effects	clostridium infections/chemically induced	0.0	0.010752688172043	0.830190299122522	0	0.0	1
anti-bacterial agents/adverse effects	escherichia coli infections/drug therapy	0.0	0.010752688172043	0.830190299122522	0	0.0	1
anti-bacterial agents/adverse effects	virus diseases/etiology	0.0	0.010752688172043	0.830190299122522	0	0.0	1
clostridium infections/chemically induced	escherichia coli infections/drug therapy	0.0	0.010752688172043	0.830190299122522	0	0.0	1
clostridium infections/chemically induced	virus diseases/etiology	0.0	0.010752688172043	0.830190299122522	0	0.0	1
escherichia coli infections/drug therapy	virus diseases/etiology	0.0	0.010752688172043	0.830190299122522	0	0.0	1
anti-bacterial agents/pharmacology	antineoplastic agents immunological/adverse effects	0.0004491699823134	0.075268817204301	0.830190299122522	0	0.0001577274046907	1
anti-bacterial agents/pharmacology	colitis/etiology	4.30833797561952e-07	0.021505376344086	0.830190299122522	0	6.54831243673826e-08	1
anti-bacterial agents/pharmacology	dysbiosis/etiology	0.0	0.010752688172043	0.830190299122522	0	0.0	1
anti-bacterial agents/pharmacology	host microbial interactions/drug effects	0.0	0.010752688172043	0.830190299122522	0	0.0	1
anti-bacterial agents/pharmacology	metabolome/drug effects	0.0	0.010752688172043	0.830190299122522	0	0.0	1
anti-bacterial agents/pharmacology	neoplasms/complications	4.18603531383465e-08	0.032258064516129	0.830190299122522	0	5.79199854744417e-09	1
antineoplastic agents immunological/adverse effects	antibodies monoclonal/adverse effects	0.0057564846974571	0.075268817204301	0.830190299122522	0	0.0029295317826157	1
antineoplastic agents immunological/adverse effects	colitis ulcerative/chemically induced	0.0021230700654632	0.075268817204301	0.830190299122522	0	0.0009302340538402	1
antineoplastic agents immunological/adverse effects	ctla-4 antigen/antagonists & inhibitors	0.0025284391813537	0.0141870751968928	0.584635003932401	0	0.0011131493251242	2
antineoplastic agents immunological/adverse effects	cytomegalovirus infections/diagnosis	3.71569203098195e-08	0.075268817204301	0.830190299122522	0	5.063311991904131e-09	1
antineoplastic agents immunological/adverse effects	dysbiosis/etiology	0.0004491699823134	0.075268817204301	0.830190299122522	0	0.0001577274046907	1
antineoplastic agents immunological/adverse effects	hashimoto disease/chemically induced	0.0021230700654632	0.075268817204301	0.830190299122522	0	0.0009302340538402	1
antineoplastic agents immunological/adverse effects	host microbial interactions/drug effects	0.0004491699823134	0.075268817204301	0.830190299122522	0	0.0001577274046907	1
antineoplastic agents immunological/adverse effects	lymphocytes/drug effects	0.0057564846974571	0.075268817204301	0.830190299122522	0	0.0029295317826157	1
antineoplastic agents immunological/adverse effects	metabolome/drug effects	0.0004491699823134	0.075268817204301	0.830190299122522	0	0.0001577274046907	1
antineoplastic agents immunological/adverse effects	neutrophils/drug effects	0.0057564846974571	0.075268817204301	0.830190299122522	0	0.0029295317826157	1
antineoplastic agents immunological/adverse effects	paclitaxel/therapeutic use	0.0021230700654632	0.075268817204301	0.830190299122522	0	0.0009302340538402	1
antineoplastic agents immunological/adverse effects	programmed cell death 1 receptor/antagonists & inhibitors	0.0092203156239976	0.012719967331643	0.347909608055624	0	0.0049629267011769	3
antineoplastic agents immunological/adverse effects	squamous cell carcinoma of head and neck/drug therapy	0.0021230700654632	0.075268817204301	0.830190299122522	0	0.0009302340538402	1
antineoplastic agents immunological/adverse effects	tongue neoplasms/drug therapy	0.0021230700654632	0.075268817204301	0.830190299122522	0	0.0009302340538402	1
antineoplastic agents immunological/adverse effects	vitamin d	2.87394303438993e-06	0.075268817204301	0.830190299122522	0	4.50371576143915e-07	1
antineoplastic agents immunological/adverse effects	vitamin d/administration & dosage	0.0057564846974571	0.075268817204301	0.830190299122522	0	0.0029295317826157	1
colitis/etiology	cd8-positive t-lymphocytes/immunology	0.0006602566909052	0.021505376344086	0.830190299122522	0	0.000267839978386	1
colitis/etiology	cytotoxicity immunologic	0.0006602566909052	0.021505376344086	0.830190299122522	0	0.000267839978386	1
colitis/etiology	drug-related side effects and adverse reactions/prevention & control	0.0006602566909052	0.021505376344086	0.830190299122522	0	0.000267839978386	1
colitis/etiology	dysbiosis/etiology	4.30833797561952e-07	0.021505376344086	0.830190299122522	0	6.54831243673826e-08	1
colitis/etiology	growth inhibitors/therapeutic use	0.0006602566909052	0.021505376344086	0.830190299122522	0	0.000267839978386	1
colitis/etiology	host microbial interactions/drug effects	4.30833797561952e-07	0.021505376344086	0.830190299122522	0	6.54831243673826e-08	1
colitis/etiology	lymphocytes tumor-infiltrating/immunology	0.0006602566909052	0.021505376344086	0.830190299122522	0	0.000267839978386	1
colitis/etiology	metabolome/drug effects	4.30833797561952e-07	0.021505376344086	0.830190299122522	0	6.54831243673826e-08	1
colitis/etiology	MTOR	0.0006602566909052	0.021505376344086	0.830190299122522	0	0.000267839978386	1
colitis/etiology	neoplasms/complications	0.0028224172203267	0.0638148667601683	0.830190299122522	0	0.0012943475198039	1
colitis/etiology	phosphatidylinositol 3-kinases/metabolism	0.0006602566909052	0.021505376344086	0.830190299122522	0	0.000267839978386	1
colitis/etiology	sirolimus/therapeutic use	0.0006602566909052	0.021505376344086	0.830190299122522	0	0.000267839978386	1
dysbiosis/etiology	host microbial interactions/drug effects	0.0	0.010752688172043	0.830190299122522	0	0.0	1
dysbiosis/etiology	metabolome/drug effects	0.0	0.010752688172043	0.830190299122522	0	0.0	1
dysbiosis/etiology	neoplasms/complications	4.18603531383465e-08	0.032258064516129	0.830190299122522	0	5.79199854744417e-09	1
host microbial interactions/drug effects	metabolome/drug effects	0.0	0.010752688172043	0.830190299122522	0	0.0	1
host microbial interactions/drug effects	neoplasms/complications	4.18603531383465e-08	0.032258064516129	0.830190299122522	0	5.79199854744417e-09	1
metabolome/drug effects	neoplasms/complications	4.18603531383465e-08	0.032258064516129	0.830190299122522	0	5.79199854744417e-09	1
neoplasms/complications	colitis/epidemiology	3.1191098568837304e-09	0.032258064516129	0.830190299122522	0	3.02429414844596e-10	1
neoplasms/complications	inflammatory bowel diseases/complications	1.95500431133e-06	0.0638148667601683	0.830190299122522	0	3.03292073455808e-07	1
antibodies monoclonal humanized	endometrial neoplasms/drug therapy	0.0	0.010752688172043	0.830190299122522	0	0.0	1
antibodies monoclonal humanized	immune checkpoint inhibitors	0.0088335817030947	0.319148936170213	0.819246405977949	1	0.004953734053108	1
antibodies monoclonal humanized	neoplasm recurrence local/drug therapy	0.0	0.010752688172043	0.830190299122522	0	0.0	1
endometrial neoplasms/drug therapy	immune checkpoint inhibitors	0.0088335817030947	0.319148936170213	0.819246405977949	1	0.004953734053108	1
endometrial neoplasms/drug therapy	neoplasm recurrence local/drug therapy	0.0	0.010752688172043	0.830190299122522	0	0.0	1
immune checkpoint inhibitors	carcinoma non-small-cell lung	0.0008472540658465	0.32258064516129	0.830190299122522	0	0.0003476938855124	1
immune checkpoint inhibitors	cd8-positive t-lymphocytes	0.0008472540658465	0.32258064516129	0.830190299122522	0	0.0003476938855124	1
immune checkpoint inhibitors	colitis	0.000242420636138	0.0969899665551839	0.347909608055624	0	6.68308462309364e-05	3
immune checkpoint inhibitors	colitis microscopic/chemically induced	7.74320237197327e-09	0.101683029453015	0.584635003932401	0	8.11341549500355e-10	2
immune checkpoint inhibitors	colitis ulcerative	3.1191098568837304e-09	0.32258064516129	0.830190299122522	0	3.02429414844596e-10	1
immune checkpoint inhibitors	colitis/chemically induced	0.0001229391146904	0.814358314952549	8.37008936595782e-13	0	3.34409855997642e-05	21
immune checkpoint inhibitors	colitis/therapy	4.04909487377475e-05	0.32258064516129	0.830190299122522	0	9.99540715695968e-06	1
immune checkpoint inhibitors	crohn disease/drug therapy	4.04909487377475e-05	0.32258064516129	0.830190299122522	0	9.99540715695968e-06	1
immune checkpoint inhibitors	cytomegalovirus infections/complications	4.04909487377475e-05	0.32258064516129	0.830190299122522	0	9.99540715695968e-06	1
immune checkpoint inhibitors	diarrhea	3.35565966893547e-05	0.101683029453015	0.584635003932401	0	5.90933778177316e-06	2
immune checkpoint inhibitors	diarrhea/therapy	0.0008472540658465	0.32258064516129	0.830190299122522	0	0.0003476938855124	1
immune checkpoint inhibitors	esophagitis	0.0008472540658465	0.32258064516129	0.830190299122522	0	0.0003476938855124	1
immune checkpoint inhibitors	immunologic factors	7.74320237197327e-09	0.101683029453015	0.584635003932401	0	8.11341549500355e-10	2
immune checkpoint inhibitors	LTF	0.0088335817030947	0.319148936170213	0.819246405977949	1	0.004953734053108	1
immune checkpoint inhibitors	lung neoplasms	0.0008472540658465	0.32258064516129	0.830190299122522	0	0.0003476938855124	1
immune checkpoint inhibitors	neoplasm recurrence local/drug therapy	0.0088335817030947	0.319148936170213	0.819246405977949	1	0.004953734053108	1
immune checkpoint inhibitors	neoplasms	0.0050567546315748	0.387959866220736	0.584635003932401	0	0.0025310276064748	2
immune checkpoint inhibitors	neoplasms/therapy	0.0008472540658465	0.32258064516129	0.830190299122522	0	0.0003476938855124	1
immune checkpoint inhibitors	prednisolone/therapeutic use	0.0043003454135787	0.32258064516129	0.830190299122522	0	0.0021298880586121	1
immune checkpoint inhibitors	ulcer/chemically induced	0.0008472540658465	0.32258064516129	0.830190299122522	0	0.0003476938855124	1
antibodies monoclonal humanized/administration & dosage	dose-response relationship drug	1.64352498622519e-08	0.021505376344086	0.830190299122522	0	2.16207951542202e-09	1
antibodies monoclonal humanized/administration & dosage	drugs investigational/administration & dosage	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
antibodies monoclonal humanized/administration & dosage	immune checkpoint inhibitors/administration & dosage	0.0037694605453253	0.043010752688172	0.830190299122522	0	0.0017670866860923	1
antibodies monoclonal humanized/administration & dosage	neoplasms/diagnosis	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
dose-response relationship drug	drugs investigational/administration & dosage	1.64352498622519e-08	0.021505376344086	0.830190299122522	0	2.16207951542202e-09	1
dose-response relationship drug	feces	1.66608300189816e-14	0.021505376344086	0.830190299122522	0	7.771561172376101e-16	1
dose-response relationship drug	neoplasms/diagnosis	1.64352498622519e-08	0.021505376344086	0.830190299122522	0	2.16207951542202e-09	1
dose-response relationship drug	steroids/therapeutic use	2.18172968216169e-09	0.0427769985974754	0.830190299122522	0	2.0925394750293e-10	1
dose-response relationship drug	colitis ulcerative/drug therapy	0.0022803239137111	0.121080627099664	0.8148056077504143	2	0.001081244496884	1
dose-response relationship drug	feces/chemistry	0.0022803239137111	0.0917833146696528	0.8148056077504143	2	0.001081244496884	1
dose-response relationship drug	leukocyte l1 antigen complex/analysis	0.0022803239137111	0.0917833146696528	0.8148056077504143	2	0.001081244496884	1
dose-response relationship drug	diarrhea/etiology	9.08633728566805e-07	0.03125	0.8148056077504143	2	1.439032364380921e-07	1
dose-response relationship drug	gastrointestinal hemorrhage/etiology	9.08633728566805e-07	0.03125	0.8148056077504143	2	1.439032364380921e-07	1
dose-response relationship drug	prednisolone/administration & dosage	9.08633728566805e-07	0.03125	0.8148056077504143	2	1.439032364380921e-07	1
dose-response relationship drug	glucocorticoids/administration & dosage	9.08633728566805e-07	0.03125	0.8148056077504143	2	1.439032364380921e-07	1
dose-response relationship drug	abdominal pain/etiology	9.08633728566805e-07	0.03125	0.8148056077504143	2	1.439032364380921e-07	1
drugs investigational/administration & dosage	immune checkpoint inhibitors/administration & dosage	0.0037694605453253	0.043010752688172	0.830190299122522	0	0.0017670866860923	1
drugs investigational/administration & dosage	neoplasms/diagnosis	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
immune checkpoint inhibitors/administration & dosage	APC	0.0045434487261055	0.0014025245441795	0.584635003932401	0	0.0022669618381826	2
immune checkpoint inhibitors/administration & dosage	neoplasms/diagnosis	0.0037694605453253	0.043010752688172	0.830190299122522	0	0.0017670866860923	1
antibodies monoclonal humanized/therapeutic use	infliximab/adverse effects	9.068402745145001e-11	0.043010752688172	0.830190299122522	0	6.36879438076221e-12	1
antibodies monoclonal humanized/therapeutic use	steroids/adverse effects	0.0	0.010752688172043	0.830190299122522	0	0.0	1
infliximab/adverse effects	colon/diagnostic imaging	6.44172677537221e-05	0.043010752688172	0.830190299122522	0	1.69483587066921e-05	1
infliximab/adverse effects	drug resistance/immunology	6.44172677537221e-05	0.043010752688172	0.830190299122522	0	1.69483587066921e-05	1
infliximab/adverse effects	glucocorticoids/pharmacology	6.44172677537221e-05	0.043010752688172	0.830190299122522	0	1.69483587066921e-05	1
infliximab/adverse effects	immunosuppressive agents/pharmacology	6.44172677537221e-05	0.043010752688172	0.830190299122522	0	1.69483587066921e-05	1
infliximab/adverse effects	intestinal mucosa/diagnostic imaging	6.44172677537221e-05	0.043010752688172	0.830190299122522	0	1.69483587066921e-05	1
infliximab/adverse effects	LTF	7.74320237197327e-09	0.043010752688172	0.830190299122522	0	8.488771907622091e-10	1
infliximab/adverse effects	melanoma/drug therapy	1.42204843155383e-05	0.0134138885892041	0.584635003932401	0	2.48187697959867e-06	2
infliximab/adverse effects	mucositis/chemically induced	6.44172677537221e-05	0.043010752688172	0.830190299122522	0	1.69483587066921e-05	1
infliximab/adverse effects	neoplasms	0.0007520276236272	0.163750819851802	0.830190299122522	0	0.0003058560984983	1
infliximab/adverse effects	steroids/adverse effects	9.068402745145001e-11	0.043010752688172	0.830190299122522	0	6.36879438076221e-12	1
antibodies monoclonal/adverse effects	ctla-4 antigen/antagonists & inhibitors	0.0010339756892922	0.032258064516129	0.830190299122522	0	0.000426487876034	1
antibodies monoclonal/adverse effects	lymphocytes/drug effects	7.74320237197327e-09	0.010752688172043	0.830190299122522	0	9.98337412738692e-10	1
antibodies monoclonal/adverse effects	neutrophils/drug effects	7.74320237197327e-09	0.010752688172043	0.830190299122522	0	9.98337412738692e-10	1
antibodies monoclonal/adverse effects	vitamin d/administration & dosage	7.74320237197327e-09	0.010752688172043	0.830190299122522	0	9.98337412738692e-10	1
ctla-4 antigen/antagonists & inhibitors	CTLA4	0.0050448673728049	0.0016953593391181	0.347909608055624	0	0.0025224336864024	3
ctla-4 antigen/antagonists & inhibitors	immunologic memory/drug effects	0.0027490210933488	0.032258064516129	0.830190299122522	0	0.0012578068210133	1
ctla-4 antigen/antagonists & inhibitors	interferon-gamma/metabolism	0.0027490210933488	0.032258064516129	0.830190299122522	0	0.0012578068210133	1
ctla-4 antigen/antagonists & inhibitors	lymphocytes/drug effects	0.0010339756892922	0.032258064516129	0.830190299122522	0	0.000426487876034	1
ctla-4 antigen/antagonists & inhibitors	neutrophils/drug effects	0.0010339756892922	0.032258064516129	0.830190299122522	0	0.000426487876034	1
ctla-4 antigen/antagonists & inhibitors	programmed cell death 1 receptor/antagonists & inhibitors	0.0011594003543304	0.0004315460135936	0.347909608055624	0	0.0004806528722617	3
ctla-4 antigen/antagonists & inhibitors	vitamin d/administration & dosage	0.0010339756892922	0.032258064516129	0.830190299122522	0	0.000426487876034	1
lymphocytes/drug effects	neutrophils/drug effects	7.74320237197327e-09	0.010752688172043	0.830190299122522	0	9.98337412738692e-10	1
lymphocytes/drug effects	vitamin d/administration & dosage	7.74320237197327e-09	0.010752688172043	0.830190299122522	0	9.98337412738692e-10	1
neutrophils/drug effects	vitamin d/administration & dosage	7.74320237197327e-09	0.010752688172043	0.830190299122522	0	9.98337412738692e-10	1
colitis ulcerative/chemically induced	hashimoto disease/chemically induced	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
colitis ulcerative/chemically induced	nivolumab/adverse effects	0.0067591691408641	0.129032258064516	0.830190299122522	0	0.0036027646835737	1
colitis ulcerative/chemically induced	paclitaxel/therapeutic use	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
colitis ulcerative/chemically induced	squamous cell carcinoma of head and neck/drug therapy	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
colitis ulcerative/chemically induced	tongue neoplasms/drug therapy	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
hashimoto disease/chemically induced	nivolumab/adverse effects	0.0067591691408641	0.129032258064516	0.830190299122522	0	0.0036027646835737	1
hashimoto disease/chemically induced	paclitaxel/therapeutic use	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
hashimoto disease/chemically induced	squamous cell carcinoma of head and neck/drug therapy	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
hashimoto disease/chemically induced	tongue neoplasms/drug therapy	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
paclitaxel/therapeutic use	nivolumab/adverse effects	0.0067591691408641	0.129032258064516	0.830190299122522	0	0.0036027646835737	1
paclitaxel/therapeutic use	squamous cell carcinoma of head and neck/drug therapy	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
paclitaxel/therapeutic use	tongue neoplasms/drug therapy	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
programmed cell death 1 receptor/antagonists & inhibitors	colitis/epidemiology	0.0052393531932329	0.086021505376344	0.830190299122522	0	0.0026251685810957	1
squamous cell carcinoma of head and neck/drug therapy	nivolumab/adverse effects	0.0067591691408641	0.129032258064516	0.830190299122522	0	0.0036027646835737	1
squamous cell carcinoma of head and neck/drug therapy	tongue neoplasms/drug therapy	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
tongue neoplasms/drug therapy	nivolumab/adverse effects	0.0067591691408641	0.129032258064516	0.830190299122522	0	0.0036027646835737	1
vitamin d	melanoma/drug therapy	1.23515805518726e-08	0.053763440860215	0.830190299122522	0	1.5989729540422102e-09	1
biomarkers/analysis	colitis/drug therapy	1.50681043810751e-07	0.032258064516129	0.830190299122522	0	2.25073886195304e-08	1
biomarkers/analysis	feces/chemistry	0.0	0.010752688172043	0.830190299122522	0	0.0	1
biomarkers/analysis	leukocyte l1 antigen complex/analysis	0.0	0.010752688172043	0.830190299122522	0	0.0	1
biomarkers/analysis	recurrence	0.0032722311928437	0.0423244108899565	0.819246405977949	1	0.0016585720850001	1
biomarkers/analysis	colitis ulcerative/drug therapy	0.0071675746314898	0.121080627099664	0.8148056077504143	2	0.0040639119322083	1
biomarkers/analysis	diarrhea/diagnosis	4.714383859604482e-07	0.03125	0.8148056077504143	2	7.173081661981939e-08	1
biomarkers/analysis	colitis microscopic/diagnosis	4.714383859604482e-07	0.03125	0.8148056077504143	2	7.173081661981939e-08	1
recurrence	colitis	1.8672532270391797e-11	0.043010752688172	0.830190299122522	0	1.2526646386845599e-12	1
recurrence	diarrhea	0.0	0.021505376344086	0.830190299122522	0	0.0	1
recurrence	inflammatory bowel diseases	0.0	0.021505376344086	0.830190299122522	0	0.0	1
recurrence	neoplasms	1.66608300189816e-14	0.043010752688172	0.830190299122522	0	7.771561172376101e-16	1
recurrence	colitis ulcerative/drug therapy	0.0061286968322745	0.121080627099664	0.8148056077504143	2	0.0033898437981384	1
recurrence	feces/chemistry	0.0061286968322745	0.0917833146696528	0.8148056077504143	2	0.0033898437981384	1
recurrence	leukocyte l1 antigen complex/analysis	0.0061286968322745	0.0917833146696528	0.8148056077504143	2	0.0033898437981384	1
recurrence	diarrhea/diagnosis	2.726722268808768e-07	0.03125	0.8148056077504143	2	4.0705136261642856e-08	1
recurrence	colitis microscopic/diagnosis	2.726722268808768e-07	0.03125	0.8148056077504143	2	4.0705136261642856e-08	1
APC	ARG1	0.005535058163635	0.021505376344086	0.830190299122522	0	0.0028052417422615	1
APC	azoxymethane/adverse effects	0.005535058163635	0.021505376344086	0.830190299122522	0	0.0028052417422615	1
APC	b7-h1 antigen/genetics	0.0095868134237069	0.021505376344086	0.830190299122522	0	0.0052154676801927	1
APC	colonic neoplasms/drug therapy	0.005535058163635	0.021505376344086	0.830190299122522	0	0.0028052417422615	1
APC	colorectal neoplasms/drug therapy	0.0095868134237069	0.021505376344086	0.830190299122522	0	0.0052154676801927	1
APC	dextran sulfate/adverse effects	0.005535058163635	0.021505376344086	0.830190299122522	0	0.0028052417422615	1
APC	gene expression regulation neoplastic	0.0095868134237069	0.021505376344086	0.830190299122522	0	0.0052154676801927	1
APC	ht29 cells	0.0095868134237069	0.021505376344086	0.830190299122522	0	0.0052154676801927	1
APC	interleukin-17/genetics	0.0095868134237069	0.021505376344086	0.830190299122522	0	0.0052154676801927	1
APC	lymphocytes tumor-infiltrating/metabolism	0.0095868134237069	0.021505376344086	0.830190299122522	0	0.0052154676801927	1
APC	micrornas/genetics	0.0095868134237069	0.021505376344086	0.830190299122522	0	0.0052154676801927	1
APC	MIR15B	0.0095868134237069	0.021505376344086	0.830190299122522	0	0.0052154676801927	1
APC	myeloid-derived suppressor cells/metabolism	0.005535058163635	0.021505376344086	0.830190299122522	0	0.0028052417422615	1
APC	NRF1	0.0095868134237069	0.021505376344086	0.830190299122522	0	0.0052154676801927	1
APC	PARP1	0.005535058163635	0.021505376344086	0.830190299122522	0	0.0028052417422615	1
APC	phthalazines/administration & dosage	0.005535058163635	0.021505376344086	0.830190299122522	0	0.0028052417422615	1
APC	piperazines/administration & dosage	0.005535058163635	0.021505376344086	0.830190299122522	0	0.0028052417422615	1
APC	poly(adp-ribose) polymerase inhibitors/administration & dosage	0.005535058163635	0.021505376344086	0.830190299122522	0	0.0028052417422615	1
APC	t-lymphocytes cytotoxic/immunology	0.0095868134237069	0.021505376344086	0.830190299122522	0	0.0052154676801927	1
APC	TIPARP	0.005535058163635	0.021505376344086	0.830190299122522	0	0.0028052417422615	1
APC	tumor microenvironment/drug effects	0.0095868134237069	0.021505376344086	0.830190299122522	0	0.0052154676801927	1
ARG1	azoxymethane/adverse effects	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
ARG1	cell line tumor	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
ARG1	colonic neoplasms/drug therapy	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
ARG1	dextran sulfate/adverse effects	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
ARG1	drug synergism	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
ARG1	myeloid-derived suppressor cells/metabolism	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
ARG1	PARP1	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
ARG1	phthalazines/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
ARG1	piperazines/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
ARG1	poly(adp-ribose) polymerase inhibitors/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
ARG1	TIPARP	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
azoxymethane/adverse effects	cell line tumor	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
azoxymethane/adverse effects	colonic neoplasms/drug therapy	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
azoxymethane/adverse effects	dextran sulfate/adverse effects	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
azoxymethane/adverse effects	drug synergism	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
azoxymethane/adverse effects	myeloid-derived suppressor cells/metabolism	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
azoxymethane/adverse effects	PARP1	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
azoxymethane/adverse effects	phthalazines/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
azoxymethane/adverse effects	piperazines/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
azoxymethane/adverse effects	poly(adp-ribose) polymerase inhibitors/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
azoxymethane/adverse effects	TIPARP	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
b7-h1 antigen/genetics	colorectal neoplasms/drug therapy	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
b7-h1 antigen/genetics	gene expression regulation neoplastic	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
b7-h1 antigen/genetics	ht29 cells	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
b7-h1 antigen/genetics	IL17A	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
b7-h1 antigen/genetics	interleukin-17/genetics	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
b7-h1 antigen/genetics	lymphocytes tumor-infiltrating/metabolism	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
b7-h1 antigen/genetics	micrornas/genetics	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
b7-h1 antigen/genetics	MIR15B	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
b7-h1 antigen/genetics	NRF1	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
b7-h1 antigen/genetics	t-lymphocytes cytotoxic/immunology	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
b7-h1 antigen/genetics	tumor microenvironment/drug effects	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
colonic neoplasms/drug therapy	cell line tumor	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
colonic neoplasms/drug therapy	dextran sulfate/adverse effects	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
colonic neoplasms/drug therapy	drug synergism	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
colonic neoplasms/drug therapy	myeloid-derived suppressor cells/metabolism	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
colonic neoplasms/drug therapy	PARP1	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
colonic neoplasms/drug therapy	phthalazines/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
colonic neoplasms/drug therapy	piperazines/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
colonic neoplasms/drug therapy	poly(adp-ribose) polymerase inhibitors/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
colonic neoplasms/drug therapy	TIPARP	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
colorectal neoplasms/drug therapy	gene expression regulation neoplastic	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
colorectal neoplasms/drug therapy	ht29 cells	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
colorectal neoplasms/drug therapy	IL17A	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
colorectal neoplasms/drug therapy	interleukin-17/genetics	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
colorectal neoplasms/drug therapy	lymphocytes tumor-infiltrating/metabolism	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
colorectal neoplasms/drug therapy	micrornas/genetics	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
colorectal neoplasms/drug therapy	MIR15B	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
colorectal neoplasms/drug therapy	NRF1	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
colorectal neoplasms/drug therapy	t-lymphocytes cytotoxic/immunology	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
colorectal neoplasms/drug therapy	tumor microenvironment/drug effects	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
dextran sulfate/adverse effects	cell line tumor	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
dextran sulfate/adverse effects	drug synergism	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
dextran sulfate/adverse effects	myeloid-derived suppressor cells/metabolism	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
dextran sulfate/adverse effects	PARP1	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
dextran sulfate/adverse effects	phthalazines/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
dextran sulfate/adverse effects	piperazines/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
dextran sulfate/adverse effects	poly(adp-ribose) polymerase inhibitors/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
dextran sulfate/adverse effects	TIPARP	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
gene expression regulation neoplastic	ht29 cells	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
gene expression regulation neoplastic	IL17A	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
gene expression regulation neoplastic	interleukin-17/genetics	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
gene expression regulation neoplastic	lymphocytes tumor-infiltrating/metabolism	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
gene expression regulation neoplastic	micrornas/genetics	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
gene expression regulation neoplastic	MIR15B	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
gene expression regulation neoplastic	NRF1	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
gene expression regulation neoplastic	t-lymphocytes cytotoxic/immunology	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
gene expression regulation neoplastic	tumor microenvironment/drug effects	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
ht29 cells	IL17A	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
ht29 cells	interleukin-17/genetics	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
ht29 cells	lymphocytes tumor-infiltrating/metabolism	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
ht29 cells	micrornas/genetics	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
ht29 cells	MIR15B	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
ht29 cells	NRF1	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
ht29 cells	t-lymphocytes cytotoxic/immunology	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
ht29 cells	tumor microenvironment/drug effects	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
interleukin-17/genetics	IL17A	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
interleukin-17/genetics	lymphocytes tumor-infiltrating/metabolism	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
interleukin-17/genetics	micrornas/genetics	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
interleukin-17/genetics	MIR15B	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
interleukin-17/genetics	NRF1	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
interleukin-17/genetics	t-lymphocytes cytotoxic/immunology	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
interleukin-17/genetics	tumor microenvironment/drug effects	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
lymphocytes tumor-infiltrating/metabolism	IL17A	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
lymphocytes tumor-infiltrating/metabolism	micrornas/genetics	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
lymphocytes tumor-infiltrating/metabolism	MIR15B	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
lymphocytes tumor-infiltrating/metabolism	NRF1	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
lymphocytes tumor-infiltrating/metabolism	t-lymphocytes cytotoxic/immunology	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
lymphocytes tumor-infiltrating/metabolism	tumor microenvironment/drug effects	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
micrornas/genetics	IL17A	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
micrornas/genetics	MIR15B	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
micrornas/genetics	NRF1	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
micrornas/genetics	t-lymphocytes cytotoxic/immunology	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
micrornas/genetics	tumor microenvironment/drug effects	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
MIR15B	IL17A	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
MIR15B	NRF1	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
MIR15B	t-lymphocytes cytotoxic/immunology	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
MIR15B	tumor microenvironment/drug effects	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
myeloid-derived suppressor cells/metabolism	cell line tumor	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
myeloid-derived suppressor cells/metabolism	drug synergism	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
myeloid-derived suppressor cells/metabolism	PARP1	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
myeloid-derived suppressor cells/metabolism	phthalazines/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
myeloid-derived suppressor cells/metabolism	piperazines/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
myeloid-derived suppressor cells/metabolism	poly(adp-ribose) polymerase inhibitors/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
myeloid-derived suppressor cells/metabolism	TIPARP	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
NRF1	IL17A	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
NRF1	t-lymphocytes cytotoxic/immunology	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
NRF1	tumor microenvironment/drug effects	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
PARP1	cell line tumor	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
PARP1	drug synergism	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
PARP1	phthalazines/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
PARP1	piperazines/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
PARP1	poly(adp-ribose) polymerase inhibitors/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
PARP1	TIPARP	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
phthalazines/administration & dosage	cell line tumor	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
phthalazines/administration & dosage	drug synergism	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
phthalazines/administration & dosage	piperazines/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
phthalazines/administration & dosage	poly(adp-ribose) polymerase inhibitors/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
phthalazines/administration & dosage	TIPARP	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
piperazines/administration & dosage	cell line tumor	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
piperazines/administration & dosage	drug synergism	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
piperazines/administration & dosage	poly(adp-ribose) polymerase inhibitors/administration & dosage	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
piperazines/administration & dosage	TIPARP	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
poly(adp-ribose) polymerase inhibitors/administration & dosage	cell line tumor	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
poly(adp-ribose) polymerase inhibitors/administration & dosage	drug synergism	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
poly(adp-ribose) polymerase inhibitors/administration & dosage	TIPARP	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
t-lymphocytes cytotoxic/immunology	IL17A	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
t-lymphocytes cytotoxic/immunology	tumor microenvironment/drug effects	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
TIPARP	cell line tumor	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
TIPARP	drug synergism	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
tumor microenvironment/drug effects	IL17A	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
cell line tumor	cd8-positive t-lymphocytes/immunology	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
cell line tumor	cytotoxicity immunologic	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
cell line tumor	drug synergism	8.62319212289841e-05	0.0002337540906965	0.584635003932401	0	2.30042179798495e-05	2
cell line tumor	drug-related side effects and adverse reactions/prevention & control	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
cell line tumor	growth inhibitors/therapeutic use	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
cell line tumor	lymphocytes tumor-infiltrating/immunology	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
cell line tumor	MTOR	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
cell line tumor	phosphatidylinositol 3-kinases/metabolism	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
cell line tumor	sirolimus/therapeutic use	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
drug synergism	cd8-positive t-lymphocytes/immunology	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
drug synergism	cytotoxicity immunologic	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
drug synergism	drug-related side effects and adverse reactions/prevention & control	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
drug synergism	growth inhibitors/therapeutic use	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
drug synergism	lymphocytes tumor-infiltrating/immunology	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
drug synergism	MTOR	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
drug synergism	phosphatidylinositol 3-kinases/metabolism	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
drug synergism	sirolimus/therapeutic use	0.0040050466235307	0.021505376344086	0.830190299122522	0	0.0019794334203299	1
arthritis/chemically induced	CHI3L1	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
arthritis/chemically induced	CXCL8	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
arthritis/chemically induced	glucocorticoids	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
arthritis/chemically induced	IL17A	5.06045957766131e-05	0.021505376344086	0.830190299122522	0	1.3102028466272e-05	1
arthritis/chemically induced	IL6	5.06045957766131e-05	0.021505376344086	0.830190299122522	0	1.3102028466272e-05	1
CHI3L1	CXCL8	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
CHI3L1	glucocorticoids	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
CHI3L1	IL17A	5.06045957766131e-05	0.021505376344086	0.830190299122522	0	1.3102028466272e-05	1
CHI3L1	IL6	5.06045957766131e-05	0.021505376344086	0.830190299122522	0	1.3102028466272e-05	1
CXCL8	glucocorticoids	1.11967578066339e-12	0.010752688172043	0.830190299122522	0	6.98330282489224e-14	1
CXCL8	IL17A	5.06045957766131e-05	0.021505376344086	0.830190299122522	0	1.3102028466272e-05	1
CXCL8	IL6	5.06045957766131e-05	0.021505376344086	0.830190299122522	0	1.3102028466272e-05	1
glucocorticoids	IL17A	5.06045957766131e-05	0.021505376344086	0.830190299122522	0	1.3102028466272e-05	1
glucocorticoids	IL6	5.06045957766131e-05	0.021505376344086	0.830190299122522	0	1.3102028466272e-05	1
IL6	BTLA	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
IL6	CD28	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
IL6	CSF2	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
IL6	gastrointestinal neoplasms/drug therapy	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
IL6	HAVCR2	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
IL6	IL15	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
IL6	IL17C	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
IL6	IL21	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
IL6	IL4	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
IL6	immune system diseases/drug therapy	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
IL6	LIF	0.0037694605453253	0.021505376344086	0.830190299122522	0	0.0017899010765538	1
CD274	CTLA4	0.0040587169708268	0.0003490778454898	0.010308700389748	0	0.0020080863838891	7
CD274	PDCD1	0.0012774341954751	1.55572732193422e-07	2.38197855033722e-06	0	0.0005382898811121	13
b7-h1 antigen/metabolism	colitis/diagnosis	3.1774582964772e-13	0.021505376344086	0.830190299122522	0	1.56541446472147e-14	1
b7-h1 antigen/metabolism	gastrointestinal tract/metabolism	0.0	0.010752688172043	0.830190299122522	0	0.0	1
b7-h1 antigen/metabolism	inflammatory bowel diseases	3.0117521380050002e-12	0.021505376344086	0.830190299122522	0	1.95732319241415e-13	1
b7-h1 antigen/metabolism	programmed cell death 1 receptor/metabolism	0.0	0.010752688172043	0.830190299122522	0	0.0	1
colitis/diagnosis	disease susceptibility	0.0	0.021505376344086	0.830190299122522	0	0.0	1
colitis/diagnosis	gastrointestinal tract/metabolism	3.1774582964772e-13	0.021505376344086	0.830190299122522	0	1.56541446472147e-14	1
colitis/diagnosis	inflammatory bowel diseases	3.71569203098195e-08	0.0427769985974754	0.830190299122522	0	5.063311991904131e-09	1
colitis/diagnosis	postoperative complications	0.0	0.021505376344086	0.830190299122522	0	0.0	1
colitis/diagnosis	programmed cell death 1 receptor/metabolism	3.1774582964772e-13	0.021505376344086	0.830190299122522	0	1.56541446472147e-14	1
gastrointestinal tract/metabolism	inflammatory bowel diseases	3.0117521380050002e-12	0.021505376344086	0.830190299122522	0	1.95732319241415e-13	1
gastrointestinal tract/metabolism	programmed cell death 1 receptor/metabolism	0.0	0.010752688172043	0.830190299122522	0	0.0	1
inflammatory bowel diseases	colitis	3.17037834302384e-05	0.0846189808321645	0.830190299122522	0	5.56643996285633e-06	1
inflammatory bowel diseases	diarrhea	3.0117521380050002e-12	0.0427769985974754	0.830190299122522	0	1.95732319241415e-13	1
inflammatory bowel diseases	neoplasms	1.53548253129985e-06	0.0846189808321645	0.830190299122522	0	2.36599509539914e-07	1
inflammatory bowel diseases	programmed cell death 1 receptor/metabolism	3.0117521380050002e-12	0.021505376344086	0.830190299122522	0	1.95732319241415e-13	1
colitis/drug therapy	cd8-positive t-lymphocytes/cytology	0.0011838553418347	0.032258064516129	0.830190299122522	0	0.0004982368131516	1
colitis/drug therapy	chemokines/metabolism	0.0011838553418347	0.032258064516129	0.830190299122522	0	0.0004982368131516	1
colitis/drug therapy	ctla-4 antigen/immunology	0.0011838553418347	0.032258064516129	0.830190299122522	0	0.0004982368131516	1
colitis/drug therapy	diarrhea/therapy	3.9572740688727e-14	0.032258064516129	0.830190299122522	0	1.88737914186277e-15	1
colitis/drug therapy	feces/chemistry	1.50681043810751e-07	0.032258064516129	0.830190299122522	0	2.25073886195304e-08	1
colitis/drug therapy	gene expression regulation/genetics	0.0011838553418347	0.032258064516129	0.830190299122522	0	0.0004982368131516	1
colitis/drug therapy	leukocyte l1 antigen complex/analysis	1.50681043810751e-07	0.032258064516129	0.830190299122522	0	2.25073886195304e-08	1
colitis/drug therapy	melanoma/genetics	0.0011838553418347	0.032258064516129	0.830190299122522	0	0.0004982368131516	1
colitis/drug therapy	multigene family	0.0011838553418347	0.032258064516129	0.830190299122522	0	0.0004982368131516	1
colitis/drug therapy	myeloid cells/cytology	0.0011838553418347	0.032258064516129	0.830190299122522	0	0.0004982368131516	1
colitis/drug therapy	neoplasms/therapy	3.9572740688727e-14	0.032258064516129	0.830190299122522	0	1.88737914186277e-15	1
colitis/drug therapy	receptors antigen t-cell/genetics	0.0011838553418347	0.032258064516129	0.830190299122522	0	0.0004982368131516	1
colitis/drug therapy	receptors cxcr3/genetics	0.0011838553418347	0.032258064516129	0.830190299122522	0	0.0004982368131516	1
colitis/drug therapy	receptors cxcr6/genetics	0.0011838553418347	0.032258064516129	0.830190299122522	0	0.0004982368131516	1
colitis/drug therapy	t-lymphocytes regulatory/cytology	0.0011838553418347	0.032258064516129	0.830190299122522	0	0.0004982368131516	1
feces/chemistry	leukocyte l1 antigen complex/analysis	0.0	0.010752688172043	0.830190299122522	0	0.0	1
feces/chemistry	colitis ulcerative/drug therapy	7.383066068623737e-11	0.0038913773796192	0.5583234571556446	2	6.287970144569499e-12	2
feces/chemistry	diarrhea/etiology	2.2510066804802509e-07	0.03125	0.8148056077504143	2	3.338813736597501e-08	1
feces/chemistry	gastrointestinal hemorrhage/etiology	2.2510066804802509e-07	0.03125	0.8148056077504143	2	3.338813736597501e-08	1
feces/chemistry	prednisolone/administration & dosage	2.2510066804802509e-07	0.03125	0.8148056077504143	2	3.338813736597501e-08	1
feces/chemistry	glucocorticoids/administration & dosage	2.2510066804802509e-07	0.03125	0.8148056077504143	2	3.338813736597501e-08	1
feces/chemistry	diarrhea/diagnosis	1.5777265995400856e-09	0.03125	0.8148056077504143	2	1.6214007914072679e-10	1
feces/chemistry	abdominal pain/etiology	2.2510066804802509e-07	0.03125	0.8148056077504143	2	3.338813736597501e-08	1
feces/chemistry	colitis microscopic/diagnosis	1.5777265995400856e-09	0.03125	0.8148056077504143	2	1.6214007914072679e-10	1
leukocyte l1 antigen complex/analysis	colitis ulcerative/drug therapy	7.383066068623737e-11	0.0038913773796192	0.5583234571556446	2	6.287970144569499e-12	2
leukocyte l1 antigen complex/analysis	diarrhea/etiology	2.2510066804802509e-07	0.03125	0.8148056077504143	2	3.338813736597501e-08	1
leukocyte l1 antigen complex/analysis	gastrointestinal hemorrhage/etiology	2.2510066804802509e-07	0.03125	0.8148056077504143	2	3.338813736597501e-08	1
leukocyte l1 antigen complex/analysis	prednisolone/administration & dosage	2.2510066804802509e-07	0.03125	0.8148056077504143	2	3.338813736597501e-08	1
leukocyte l1 antigen complex/analysis	glucocorticoids/administration & dosage	2.2510066804802509e-07	0.03125	0.8148056077504143	2	3.338813736597501e-08	1
leukocyte l1 antigen complex/analysis	diarrhea/diagnosis	1.5777265995400856e-09	0.03125	0.8148056077504143	2	1.6214007914072679e-10	1
leukocyte l1 antigen complex/analysis	abdominal pain/etiology	2.2510066804802509e-07	0.03125	0.8148056077504143	2	3.338813736597501e-08	1
leukocyte l1 antigen complex/analysis	colitis microscopic/diagnosis	1.5777265995400856e-09	0.03125	0.8148056077504143	2	1.6214007914072679e-10	1
BTLA	CD28	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
BTLA	CSF2	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
BTLA	gastrointestinal neoplasms/drug therapy	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
BTLA	HAVCR2	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
BTLA	IL15	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
BTLA	IL17C	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
BTLA	IL21	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
BTLA	IL4	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
BTLA	immune system diseases/drug therapy	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
BTLA	LIF	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
CD28	CSF2	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
CD28	gastrointestinal neoplasms/drug therapy	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
CD28	HAVCR2	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
CD28	IL15	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
CD28	IL17C	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
CD28	IL21	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
CD28	IL4	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
CD28	immune system diseases/drug therapy	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
CD28	LIF	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
CSF2	gastrointestinal neoplasms/drug therapy	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
CSF2	HAVCR2	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
CSF2	IL15	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
CSF2	IL17C	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
CSF2	IL21	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
CSF2	IL4	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
CSF2	immune system diseases/drug therapy	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
CSF2	LIF	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
gastrointestinal neoplasms/drug therapy	HAVCR2	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
gastrointestinal neoplasms/drug therapy	IL15	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
gastrointestinal neoplasms/drug therapy	IL17C	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
gastrointestinal neoplasms/drug therapy	IL21	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
gastrointestinal neoplasms/drug therapy	IL4	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
gastrointestinal neoplasms/drug therapy	immune system diseases/drug therapy	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
gastrointestinal neoplasms/drug therapy	LIF	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
HAVCR2	IL15	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
HAVCR2	IL17C	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
HAVCR2	IL21	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
HAVCR2	IL4	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
HAVCR2	immune system diseases/drug therapy	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
HAVCR2	LIF	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
IL15	IL17C	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
IL15	IL21	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
IL15	IL4	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
IL15	immune system diseases/drug therapy	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
IL15	LIF	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
IL17C	IL21	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
IL17C	IL4	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
IL17C	immune system diseases/drug therapy	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
IL17C	LIF	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
IL21	IL4	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
IL21	immune system diseases/drug therapy	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
IL21	LIF	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
IL4	immune system diseases/drug therapy	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
IL4	LIF	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
immune system diseases/drug therapy	LIF	0.0002777578837603	0.010752688172043	0.830190299122522	0	9.37505645396408e-05	1
carcinoma non-small-cell lung	cd8-positive t-lymphocytes	0.0	0.010752688172043	0.830190299122522	0	0.0	1
carcinoma non-small-cell lung/drug therapy	nivolumab/adverse effects	0.0081551678971482	0.240219629375429	0.819246405977949	1	0.0045533020759077	1
nivolumab/adverse effects	colitis/chemically induced	0.0077230980883216	0.351518422440415	0.0002278681042509	0	0.0041246524905659	10
nivolumab/adverse effects	disease susceptibility	3.54050817950207e-05	0.129032258064516	0.830190299122522	0	8.27983542073252e-06	1
nivolumab/adverse effects	drug-related side effects and adverse reactions/diagnosis	0.0007520276236272	0.129032258064516	0.830190299122522	0	0.0003058560984983	1
nivolumab/adverse effects	ipilimumab/adverse effects	0.0	2.70981274267652e-06	0.010308700389748	0	0.0	7
nivolumab/adverse effects	lung neoplasms/drug therapy	0.0067591691408641	0.242636746143057	0.830190299122522	0	0.0036027646835737	1
nivolumab/adverse effects	oropharyngeal neoplasms/drug therapy	3.54050817950207e-05	0.129032258064516	0.830190299122522	0	8.27983542073252e-06	1
nivolumab/adverse effects	postoperative complications	3.54050817950207e-05	0.129032258064516	0.830190299122522	0	8.27983542073252e-06	1
nivolumab/adverse effects	prednisolone/therapeutic use	3.54050817950207e-05	0.129032258064516	0.830190299122522	0	8.27983542073252e-06	1
nivolumab/adverse effects	protein kinase inhibitors/therapeutic use	0.0020084704002361	0.129032258064516	0.830190299122522	0	0.000872653019809	1
inflammatory bowel diseases/drug therapy	CD4	0.0005814517869145	0.0638148667601683	0.830190299122522	0	0.0002334339983105	1
inflammatory bowel diseases/drug therapy	CD68	0.0005814517869145	0.0638148667601683	0.830190299122522	0	0.0002334339983105	1
inflammatory bowel diseases/drug therapy	colitis	0.0005814517869145	0.124855509147234	0.830190299122522	0	0.0002334339983105	1
inflammatory bowel diseases/drug therapy	CTLA4	0.0085206844195631	0.042892591279688	0.584635003932401	0	0.0045640144008352	2
inflammatory bowel diseases/drug therapy	proton pump inhibitors/adverse effects	1.8672532270391797e-11	0.032258064516129	0.830190299122522	0	1.2526646386845599e-12	1
CTLA4	colitis	0.0085206844195631	0.0795123530046391	0.584635003932401	0	0.0045640144008352	2
CTLA4	PDCD1	0.0028224172203267	7.40082614672845e-07	5.36975220686589e-05	0	0.001293939617514	11
CTLA4	pneumonia	0.0088485763880946	0.125	0.8148056077504143	2	0.0051355613199802	1
CTLA4	drug-related side effects and adverse reactions/diagnosis	0.0088485763880946	0.125	0.8148056077504143	2	0.0051355613199802	1
CTLA4	ligands	0.0088485763880946	0.125	0.8148056077504143	2	0.0051355613199802	1
PDCD1	inflammatory bowel diseases/complications	0.0094643775593189	0.0686341798215511	0.565811148340234	1	0.0053956230889646	2
CD4	CD68	2.9921065625160297e-12	0.0002337540906965	0.584635003932401	0	1.88182802673964e-13	2
CD4	cd8-positive t-lymphocytes/drug effects	0.0026891839170452	0.0427769985974754	0.830190299122522	0	0.0012219719371479	1
CD4	CD8A	0.0005814517869145	0.0023375409069658	0.584635003932401	0	0.0002095106790775	2
CD4	colitis ulcerative/immunology	0.0026891839170452	0.0427769985974754	0.830190299122522	0	0.0012219719371479	1
CD4	crohn disease/immunology	3.69687694073866e-06	0.021505376344086	0.830190299122522	0	6.08395890666635e-07	1
CD4	graft vs host disease/immunology	3.69687694073866e-06	0.021505376344086	0.830190299122522	0	6.08395890666635e-07	1
CD4	macrophages/drug effects	3.69687694073866e-06	0.021505376344086	0.830190299122522	0	6.08395890666635e-07	1
CD4	phenotype	0.0026891839170452	0.0427769985974754	0.830190299122522	0	0.0012219719371479	1
CD68	cd8-positive t-lymphocytes/drug effects	0.0026891839170452	0.0427769985974754	0.830190299122522	0	0.0012219719371479	1
CD68	CD8A	0.0005814517869145	0.0023375409069658	0.584635003932401	0	0.0002095106790775	2
CD68	colitis ulcerative/immunology	0.0026891839170452	0.0427769985974754	0.830190299122522	0	0.0012219719371479	1
CD68	crohn disease/immunology	3.69687694073866e-06	0.021505376344086	0.830190299122522	0	6.08395890666635e-07	1
CD68	graft vs host disease/immunology	3.69687694073866e-06	0.021505376344086	0.830190299122522	0	6.08395890666635e-07	1
CD68	macrophages/drug effects	3.69687694073866e-06	0.021505376344086	0.830190299122522	0	6.08395890666635e-07	1
CD68	phenotype	0.0026891839170452	0.0427769985974754	0.830190299122522	0	0.0012219719371479	1
cd8-positive t-lymphocytes/drug effects	CD8A	0.0029452055620332	0.0023375409069658	0.584635003932401	0	0.0013552885133465	2
cd8-positive t-lymphocytes/drug effects	colitis ulcerative/immunology	9.94826330498929e-08	0.0002337540906965	0.584635003932401	0	1.40216387389813e-08	2
cd8-positive t-lymphocytes/drug effects	crohn disease/immunology	4.30118631762015e-05	0.021505376344086	0.830190299122522	0	1.09558519411079e-05	1
cd8-positive t-lymphocytes/drug effects	graft vs host disease/immunology	4.30118631762015e-05	0.021505376344086	0.830190299122522	0	1.09558519411079e-05	1
cd8-positive t-lymphocytes/drug effects	immunologic memory/drug effects	0.0003619960532727	0.021505376344086	0.830190299122522	0	0.000124270133592	1
cd8-positive t-lymphocytes/drug effects	interferon-gamma/metabolism	0.0003619960532727	0.021505376344086	0.830190299122522	0	0.000124270133592	1
cd8-positive t-lymphocytes/drug effects	macrophages/drug effects	4.30118631762015e-05	0.021505376344086	0.830190299122522	0	1.09558519411079e-05	1
cd8-positive t-lymphocytes/drug effects	phenotype	9.94826330498929e-08	0.0002337540906965	0.584635003932401	0	1.40216387389813e-08	2
cd8-positive t-lymphocytes/drug effects	piperidines/therapeutic use	0.0044825178297132	0.0427769985974754	0.830190299122522	0	0.0022342109308476	1
cd8-positive t-lymphocytes/drug effects	pyrimidines/therapeutic use	0.0044825178297132	0.0427769985974754	0.830190299122522	0	0.0022342109308476	1
CD8A	colitis ulcerative/immunology	0.0029452055620332	0.0023375409069658	0.584635003932401	0	0.0013552885133465	2
CD8A	phenotype	0.0029452055620332	0.0023375409069658	0.584635003932401	0	0.0013552885133465	2
colitis ulcerative/immunology	crohn disease/immunology	4.30118631762015e-05	0.021505376344086	0.830190299122522	0	1.09558519411079e-05	1
colitis ulcerative/immunology	graft vs host disease/immunology	4.30118631762015e-05	0.021505376344086	0.830190299122522	0	1.09558519411079e-05	1
colitis ulcerative/immunology	immunologic memory/drug effects	0.0003619960532727	0.021505376344086	0.830190299122522	0	0.000124270133592	1
colitis ulcerative/immunology	interferon-gamma/metabolism	0.0003619960532727	0.021505376344086	0.830190299122522	0	0.000124270133592	1
colitis ulcerative/immunology	macrophages/drug effects	4.30118631762015e-05	0.021505376344086	0.830190299122522	0	1.09558519411079e-05	1
colitis ulcerative/immunology	phenotype	9.94826330498929e-08	0.0002337540906965	0.584635003932401	0	1.40216387389813e-08	2
colitis ulcerative/immunology	piperidines/therapeutic use	0.0044825178297132	0.0427769985974754	0.830190299122522	0	0.0022342109308476	1
colitis ulcerative/immunology	pyrimidines/therapeutic use	0.0044825178297132	0.0427769985974754	0.830190299122522	0	0.0022342109308476	1
crohn disease/immunology	graft vs host disease/immunology	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
crohn disease/immunology	macrophages/drug effects	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
crohn disease/immunology	phenotype	4.30118631762015e-05	0.021505376344086	0.830190299122522	0	1.09558519411079e-05	1
graft vs host disease/immunology	macrophages/drug effects	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
graft vs host disease/immunology	phenotype	4.30118631762015e-05	0.021505376344086	0.830190299122522	0	1.09558519411079e-05	1
macrophages/drug effects	phenotype	4.30118631762015e-05	0.021505376344086	0.830190299122522	0	1.09558519411079e-05	1
phenotype	immunologic memory/drug effects	0.0003619960532727	0.021505376344086	0.830190299122522	0	0.000124270133592	1
phenotype	interferon-gamma/metabolism	0.0003619960532727	0.021505376344086	0.830190299122522	0	0.000124270133592	1
phenotype	piperidines/therapeutic use	0.0044825178297132	0.0427769985974754	0.830190299122522	0	0.0022342109308476	1
phenotype	pyrimidines/therapeutic use	0.0044825178297132	0.0427769985974754	0.830190299122522	0	0.0022342109308476	1
cd8-positive t-lymphocytes/cytology	chemokines/metabolism	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cd8-positive t-lymphocytes/cytology	ctla-4 antigen/immunology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cd8-positive t-lymphocytes/cytology	gene expression regulation/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cd8-positive t-lymphocytes/cytology	melanoma/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cd8-positive t-lymphocytes/cytology	multigene family	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cd8-positive t-lymphocytes/cytology	myeloid cells/cytology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cd8-positive t-lymphocytes/cytology	receptors antigen t-cell/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cd8-positive t-lymphocytes/cytology	receptors cxcr3/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cd8-positive t-lymphocytes/cytology	receptors cxcr6/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cd8-positive t-lymphocytes/cytology	t-lymphocytes regulatory/cytology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
chemokines/metabolism	ctla-4 antigen/immunology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
chemokines/metabolism	gene expression regulation/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
chemokines/metabolism	melanoma/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
chemokines/metabolism	multigene family	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
chemokines/metabolism	myeloid cells/cytology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
chemokines/metabolism	receptors antigen t-cell/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
chemokines/metabolism	receptors cxcr3/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
chemokines/metabolism	receptors cxcr6/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
chemokines/metabolism	t-lymphocytes regulatory/cytology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
ctla-4 antigen/immunology	gene expression regulation/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
ctla-4 antigen/immunology	melanoma/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
ctla-4 antigen/immunology	multigene family	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
ctla-4 antigen/immunology	myeloid cells/cytology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
ctla-4 antigen/immunology	receptors antigen t-cell/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
ctla-4 antigen/immunology	receptors cxcr3/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
ctla-4 antigen/immunology	receptors cxcr6/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
ctla-4 antigen/immunology	t-lymphocytes regulatory/cytology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
gene expression regulation/genetics	melanoma/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
gene expression regulation/genetics	multigene family	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
gene expression regulation/genetics	myeloid cells/cytology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
gene expression regulation/genetics	receptors antigen t-cell/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
gene expression regulation/genetics	receptors cxcr3/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
gene expression regulation/genetics	receptors cxcr6/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
gene expression regulation/genetics	t-lymphocytes regulatory/cytology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
melanoma/genetics	multigene family	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
melanoma/genetics	myeloid cells/cytology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
melanoma/genetics	receptors antigen t-cell/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
melanoma/genetics	receptors cxcr3/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
melanoma/genetics	receptors cxcr6/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
melanoma/genetics	t-lymphocytes regulatory/cytology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
multigene family	myeloid cells/cytology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
multigene family	receptors antigen t-cell/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
multigene family	receptors cxcr3/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
multigene family	receptors cxcr6/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
multigene family	t-lymphocytes regulatory/cytology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
myeloid cells/cytology	receptors antigen t-cell/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
myeloid cells/cytology	receptors cxcr3/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
myeloid cells/cytology	receptors cxcr6/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
myeloid cells/cytology	t-lymphocytes regulatory/cytology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
receptors antigen t-cell/genetics	receptors cxcr3/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
receptors antigen t-cell/genetics	receptors cxcr6/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
receptors antigen t-cell/genetics	t-lymphocytes regulatory/cytology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
receptors cxcr3/genetics	receptors cxcr6/genetics	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
receptors cxcr3/genetics	t-lymphocytes regulatory/cytology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
receptors cxcr6/genetics	t-lymphocytes regulatory/cytology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
immunologic memory/drug effects	interferon-gamma/metabolism	1.66393968736404e-06	0.010752688172043	0.830190299122522	0	2.57265308056809e-07	1
immunologic memory/drug effects	piperidines/therapeutic use	0.0001340865542691	0.021505376344086	0.830190299122522	0	3.67543332718823e-05	1
immunologic memory/drug effects	pyrimidines/therapeutic use	0.0001340865542691	0.021505376344086	0.830190299122522	0	3.67543332718823e-05	1
interferon-gamma/metabolism	piperidines/therapeutic use	0.0001340865542691	0.021505376344086	0.830190299122522	0	3.67543332718823e-05	1
interferon-gamma/metabolism	pyrimidines/therapeutic use	0.0001340865542691	0.021505376344086	0.830190299122522	0	3.67543332718823e-05	1
piperidines/therapeutic use	protein kinase inhibitors/therapeutic use	9.94826330498929e-08	0.021505376344086	0.830190299122522	0	1.4077731091966e-08	1
piperidines/therapeutic use	pyrimidines/therapeutic use	4.9832894133023e-10	0.0002337540906965	0.584635003932401	0	4.5445092133888894e-11	2
pyrimidines/therapeutic use	protein kinase inhibitors/therapeutic use	9.94826330498929e-08	0.021505376344086	0.830190299122522	0	1.4077731091966e-08	1
cd8-positive t-lymphocytes/immunology	cytotoxicity immunologic	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cd8-positive t-lymphocytes/immunology	drug-related side effects and adverse reactions/prevention & control	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cd8-positive t-lymphocytes/immunology	growth inhibitors/therapeutic use	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cd8-positive t-lymphocytes/immunology	immune checkpoint inhibitors/therapeutic use	0.0063197351885054	0.021505376344086	0.830190299122522	0	0.0032890445713762	1
cd8-positive t-lymphocytes/immunology	lymphocytes tumor-infiltrating/immunology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cd8-positive t-lymphocytes/immunology	MTOR	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cd8-positive t-lymphocytes/immunology	phosphatidylinositol 3-kinases/metabolism	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cd8-positive t-lymphocytes/immunology	sirolimus/therapeutic use	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cytotoxicity immunologic	drug-related side effects and adverse reactions/prevention & control	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cytotoxicity immunologic	growth inhibitors/therapeutic use	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cytotoxicity immunologic	immune checkpoint inhibitors/therapeutic use	0.0063197351885054	0.021505376344086	0.830190299122522	0	0.0032890445713762	1
cytotoxicity immunologic	lymphocytes tumor-infiltrating/immunology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cytotoxicity immunologic	MTOR	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cytotoxicity immunologic	phosphatidylinositol 3-kinases/metabolism	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
cytotoxicity immunologic	sirolimus/therapeutic use	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
drug-related side effects and adverse reactions/prevention & control	growth inhibitors/therapeutic use	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
drug-related side effects and adverse reactions/prevention & control	immune checkpoint inhibitors/therapeutic use	0.0063197351885054	0.021505376344086	0.830190299122522	0	0.0032890445713762	1
drug-related side effects and adverse reactions/prevention & control	lymphocytes tumor-infiltrating/immunology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
drug-related side effects and adverse reactions/prevention & control	MTOR	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
drug-related side effects and adverse reactions/prevention & control	phosphatidylinositol 3-kinases/metabolism	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
drug-related side effects and adverse reactions/prevention & control	sirolimus/therapeutic use	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
growth inhibitors/therapeutic use	immune checkpoint inhibitors/therapeutic use	0.0063197351885054	0.021505376344086	0.830190299122522	0	0.0032890445713762	1
growth inhibitors/therapeutic use	lymphocytes tumor-infiltrating/immunology	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
growth inhibitors/therapeutic use	MTOR	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
growth inhibitors/therapeutic use	phosphatidylinositol 3-kinases/metabolism	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
growth inhibitors/therapeutic use	sirolimus/therapeutic use	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
immune checkpoint inhibitors/therapeutic use	lymphocytes tumor-infiltrating/immunology	0.0063197351885054	0.021505376344086	0.830190299122522	0	0.0032890445713762	1
immune checkpoint inhibitors/therapeutic use	MTOR	0.0063197351885054	0.021505376344086	0.830190299122522	0	0.0032890445713762	1
immune checkpoint inhibitors/therapeutic use	phosphatidylinositol 3-kinases/metabolism	0.0063197351885054	0.021505376344086	0.830190299122522	0	0.0032890445713762	1
immune checkpoint inhibitors/therapeutic use	sirolimus/therapeutic use	0.0063197351885054	0.021505376344086	0.830190299122522	0	0.0032890445713762	1
lymphocytes tumor-infiltrating/immunology	MTOR	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
lymphocytes tumor-infiltrating/immunology	phosphatidylinositol 3-kinases/metabolism	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
lymphocytes tumor-infiltrating/immunology	sirolimus/therapeutic use	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
MTOR	phosphatidylinositol 3-kinases/metabolism	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
MTOR	sirolimus/therapeutic use	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
phosphatidylinositol 3-kinases/metabolism	sirolimus/therapeutic use	3.54050817950207e-05	0.010752688172043	0.830190299122522	0	8.68426534594846e-06	1
colitis	diarrhea	0.0	0.0014025245441795	0.584635003932401	0	0.0	2
colitis	ligands	1.0197981792359201e-09	0.043010752688172	0.830190299122522	0	9.620737539961509e-11	1
colitis	neoplasms	0.0001015556156374	0.163750819851802	0.830190299122522	0	2.73582738142819e-05	1
colitis	pneumonia	1.0197981792359201e-09	0.043010752688172	0.830190299122522	0	9.620737539961509e-11	1
diarrhea	neoplasms	1.48140166800204e-10	0.0846189808321645	0.830190299122522	0	1.04816155754861e-11	1
ligands	pneumonia	0.0	0.010752688172043	0.830190299122522	0	0.0	1
neoplasms	LTF	1.66608300189816e-14	0.043010752688172	0.830190299122522	0	7.771561172376101e-16	1
colitis collagenous/drug therapy	skin neoplasms/complications	0.0	0.010752688172043	0.830190299122522	0	0.0	1
colitis microscopic/chemically induced	inflammatory bowel diseases/complications	0.0	0.0427769985974754	0.830190299122522	0	0.0	1
colitis ulcerative/drug therapy	crohn disease/drug therapy	0.0	0.021505376344086	0.830190299122522	0	0.0	1
colitis ulcerative/drug therapy	interleukin-12/antagonists & inhibitors	0.0	0.021505376344086	0.830190299122522	0	0.0	1
colitis ulcerative/drug therapy	interleukin-23/antagonists & inhibitors	0.0	0.021505376344086	0.830190299122522	0	0.0	1
colitis ulcerative/drug therapy	ustekinumab/therapeutic use	0.0	0.021505376344086	0.830190299122522	0	0.0	1
colitis ulcerative/drug therapy	diarrhea/etiology	2.2510066804802509e-07	0.0416666666666666	0.8148056077504143	2	3.338813736597501e-08	1
colitis ulcerative/drug therapy	gastrointestinal hemorrhage/etiology	2.2510066804802509e-07	0.0416666666666666	0.8148056077504143	2	3.338813736597501e-08	1
colitis ulcerative/drug therapy	prednisolone/administration & dosage	2.2510066804802509e-07	0.0416666666666666	0.8148056077504143	2	3.338813736597501e-08	1
colitis ulcerative/drug therapy	glucocorticoids/administration & dosage	2.2510066804802509e-07	0.0416666666666666	0.8148056077504143	2	3.338813736597501e-08	1
colitis ulcerative/drug therapy	diarrhea/diagnosis	1.5777265995400856e-09	0.0416666666666666	0.8148056077504143	2	1.6214007914072679e-10	1
colitis ulcerative/drug therapy	abdominal pain/etiology	2.2510066804802509e-07	0.0416666666666666	0.8148056077504143	2	3.338813736597501e-08	1
colitis ulcerative/drug therapy	colitis microscopic/diagnosis	1.5777265995400856e-09	0.0416666666666666	0.8148056077504143	2	1.6214007914072679e-10	1
interleukin-12/antagonists & inhibitors	interleukin-23/antagonists & inhibitors	0.0	0.010752688172043	0.830190299122522	0	0.0	1
interleukin-12/antagonists & inhibitors	ustekinumab/therapeutic use	0.0	0.010752688172043	0.830190299122522	0	0.0	1
interleukin-23/antagonists & inhibitors	ustekinumab/therapeutic use	0.0	0.010752688172043	0.830190299122522	0	0.0	1
colitis ulcerative/physiopathology	crohn disease/physiopathology	0.0	0.010752688172043	0.830190299122522	0	0.0	1
colitis/chemically induced	ipilimumab/adverse effects	0.0016423684574307	0.0589207356081562	0.0008903144156418	0	0.0007075612536729	9
ipilimumab/adverse effects	drug-related side effects and adverse reactions/diagnosis	8.14996106653217e-05	0.0967741935483871	0.830190299122522	0	2.16563430855965e-05	1
ipilimumab/adverse effects	protein kinase inhibitors/therapeutic use	0.0002777578837603	0.0967741935483871	0.830190299122522	0	8.84097061502054e-05	1
disease susceptibility	postoperative complications	0.0	0.010752688172043	0.830190299122522	0	0.0	1
diarrhea/therapy	neoplasms/therapy	0.0	0.010752688172043	0.830190299122522	0	0.0	1
colitis/therapy	immunologic factors	0.0	0.021505376344086	0.830190299122522	0	0.0	1
colon/diagnostic imaging	drug resistance/immunology	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
colon/diagnostic imaging	glucocorticoids/pharmacology	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
colon/diagnostic imaging	immunosuppressive agents/pharmacology	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
colon/diagnostic imaging	intestinal mucosa/diagnostic imaging	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
colon/diagnostic imaging	melanoma/drug therapy	0.0004664777824253	0.053763440860215	0.830190299122522	0	0.0001660054582111	1
colon/diagnostic imaging	mucositis/chemically induced	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
drug resistance/immunology	glucocorticoids/pharmacology	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
drug resistance/immunology	immunosuppressive agents/pharmacology	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
drug resistance/immunology	intestinal mucosa/diagnostic imaging	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
drug resistance/immunology	melanoma/drug therapy	0.0004664777824253	0.053763440860215	0.830190299122522	0	0.0001660054582111	1
drug resistance/immunology	mucositis/chemically induced	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
glucocorticoids/pharmacology	immunosuppressive agents/pharmacology	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
glucocorticoids/pharmacology	intestinal mucosa/diagnostic imaging	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
glucocorticoids/pharmacology	melanoma/drug therapy	0.0004664777824253	0.053763440860215	0.830190299122522	0	0.0001660054582111	1
glucocorticoids/pharmacology	mucositis/chemically induced	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
immunosuppressive agents/pharmacology	intestinal mucosa/diagnostic imaging	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
immunosuppressive agents/pharmacology	melanoma/drug therapy	0.0004664777824253	0.053763440860215	0.830190299122522	0	0.0001660054582111	1
immunosuppressive agents/pharmacology	mucositis/chemically induced	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
intestinal mucosa/diagnostic imaging	melanoma/drug therapy	0.0004664777824253	0.053763440860215	0.830190299122522	0	0.0001660054582111	1
intestinal mucosa/diagnostic imaging	mucositis/chemically induced	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
melanoma/drug therapy	mucositis/chemically induced	0.0004664777824253	0.053763440860215	0.830190299122522	0	0.0001660054582111	1
colon/immunology	intestinal mucosa/immunology	0.0	0.021505376344086	0.830190299122522	0	0.0	1
colon/immunology	t-lymphocyte subsets/immunology	0.0	0.021505376344086	0.830190299122522	0	0.0	1
CXCL10	CXCL9	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
CXCL10	dermatitis	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
CXCL10	psoriasis	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
CXCL10	rna	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
CXCL10	TCIM	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
CXCL9	dermatitis	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
CXCL9	psoriasis	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
CXCL9	rna	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
CXCL9	TCIM	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
dermatitis	psoriasis	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
dermatitis	rna	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
dermatitis	TCIM	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
psoriasis	rna	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
psoriasis	TCIM	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
rna	TCIM	1.90948322242736e-10	0.010752688172043	0.830190299122522	0	1.69131375571396e-11	1
feces	steroids/therapeutic use	0.0	0.021505376344086	0.830190299122522	0	0.0	1
steroids/therapeutic use	lung neoplasms	0.0	0.021505376344086	0.830190299122522	0	0.0	1
esophagitis	ulcer/chemically induced	0.0	0.010752688172043	0.830190299122522	0	0.0	1
prednisolone/therapeutic use	lung neoplasms/drug therapy	0.0	0.021505376344086	0.830190299122522	0	0.0	1
diarrhea/diagnosis	colitis microscopic/diagnosis	0.0	0.0104166666666666	0.8148056077504143	2	0.0	1
diarrhea/etiology	gastrointestinal hemorrhage/etiology	0.0	0.0104166666666666	0.8148056077504143	2	0.0	1
diarrhea/etiology	prednisolone/administration & dosage	0.0	0.0104166666666666	0.8148056077504143	2	0.0	1
diarrhea/etiology	glucocorticoids/administration & dosage	0.0	0.0104166666666666	0.8148056077504143	2	0.0	1
diarrhea/etiology	abdominal pain/etiology	0.0	0.0104166666666666	0.8148056077504143	2	0.0	1
gastrointestinal hemorrhage/etiology	prednisolone/administration & dosage	0.0	0.0104166666666666	0.8148056077504143	2	0.0	1
gastrointestinal hemorrhage/etiology	glucocorticoids/administration & dosage	0.0	0.0104166666666666	0.8148056077504143	2	0.0	1
gastrointestinal hemorrhage/etiology	abdominal pain/etiology	0.0	0.0104166666666666	0.8148056077504143	2	0.0	1
prednisolone/administration & dosage	glucocorticoids/administration & dosage	0.0	0.0104166666666666	0.8148056077504143	2	0.0	1
prednisolone/administration & dosage	abdominal pain/etiology	0.0	0.0104166666666666	0.8148056077504143	2	0.0	1
glucocorticoids/administration & dosage	abdominal pain/etiology	0.0	0.0104166666666666	0.8148056077504143	2	0.0	1
